



2025

Sustainable Development Report

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Phone:86-022-27020892
Official Website:www.jinyaodarentang.com.cn
Email:drt600329@163.com
Address:No. 17 Baidi Road, Nankai District, Tianjin, China

CONTENTS

About The Report 01

Chairman's Statement 03

About Da Ren Tang

Company Overview	05
Corporate Culture	08
Annual Highlights	09
Group Honours	11

Sustainability Governance

Statement from the Board of Directors	13
Sustainability Governance Structure	13
ESG Capacity Building	14
Stakeholder Engagement	15
Identification of Material Issues	15
Due Diligence	17

Ancient Craft Revitalized, Heritage Carried Forward

A Thematic Feature on Da Ren Tang's Innovative Inheritance of Intangible Cultural Heritage and Brand Communication

Upholding Intangible Cultural Heritage Roots and Inheriting the Wisdom of Traditional Chinese Medicine	21
Advancing Digital Innovation and Revitalizing the Time-Honored Brand	23
Expanding International Communication and Telling China's Intangible Cultural Heritage Story	23
Empowering the Brand through Public Welfare and Practicing the Philosophy of benefiting people's livelihood	25

Upholding Benevolence and Strengthening Our Century-Old Foundation 01

Prudent Corporate Operations	29
Compliance and Risk Control Enhancement	34
Business Ethics Adherence	36

Following the Rhythm of Nature and Safeguarding Lucid Waters and Lush Mountains 02

Environmental Compliance Management	43
Green Operations Implementation	45
Addressing Climate Change	54
Ecological Resource Protection	56

Inheriting Ancient Craftsmanship and Cultivating Talents of Shared Aspiration 03

Standardized Employment Management	61
Employee Training and Development	63
Employee Rights and Compensation	69
Employee Safety Assurance	73

Adhering to Pharmaceutical Integrity and Forging the Quality of Da Ren Tang 04

R&D Innovation Enhancement	79
Quality and Safety Assurance	82
Customer Rights and Interests Protection	91
Supply Chain Management Improvement	95

Advancing Social Benevolence and Creating Enduring Value 05

Drug Accessibility Assurance	99
Social Responsibility Enhancement	102
Rural Revitalization Support	106
Industry Development Promotion	107

Appendix of the Report 06

Key ESG Performance	111
Glossary	114
Index	115
Reader Feedback Form	116



About The Report

Report Explanation

This Report is the nineteenth Sustainable Development Report published by Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (referred to as "Da Ren Tang"). Before 2018, this Report was titled the Social Responsibility Report, and it may also be referred to as a CSR report or an ESG (Environmental, Social and Governance) Report. This Report is issued on an annual basis and focuses on disclosing our management approaches, practices, and performance in the areas of Environmental, Social, and Governance (ESG).

Scope and Boundaries of the Report

Unless otherwise specified, the information contained in this Report covers the period from 1 January 2025 to 31 December 2025 (referred to as the "Reporting Period"), with certain content extending beyond the Reporting Period. The scope of this Report encompasses Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited and its subsidiaries (referred to as "Da Ren Tang", "the Group", "the Company", or "we"). In this Report, "Da Ren Tang Group" refers specifically to the parent company of Da Ren Tang.

Other abbreviations are explained as follows:

Darentang Pharmaceutical Factory of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Darentang Pharmaceutical Factory
Long Shun Rong Pharmaceutical Factory of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Long Shun Rong Pharmaceutical Factory
Le Ren Tang Pharmaceutical Factory of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Le Ren Tang Pharmaceutical Factory
No. 6 Chinese Medicine Plant of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	No. 6 Chinese Medicine Plant
Xinxin Pharmaceutical Plant of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Xinxin Pharmaceutical Plant
Zhongxin Pharmaceutical Plant of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Zhongxin Pharmaceutical Plant
Tianjin Da Ren Tang Jingwanhong Pharmaceutical Co., Ltd.	Jingwanhong Pharmaceutical
Newscen Coast Bio-Pharmaceutical Co., Ltd.	NewScen Coast
Medicinal Materials Company of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Medicinal Materials Company

Reporting Standards

This Report has been prepared in accordance with the Mainboard Listing Rules 711A and 711B of the Singapore Exchange, the *Self-Regulatory Guidelines No. 14 for Listed Companies — Sustainability Report (Trial)* issued by the Shanghai Stock Exchange, and with reference to the *GRI Sustainability Reporting Standards (2021 Edition)* issued by the Global Sustainability Standards Board (GSSB), the *Recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD)*, and the United Nations Sustainable Development Goals (SDGs).

Data Sources and Internal Review

The data contained in this Report are derived from the internal documents and statistical information of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd. Unless specified otherwise, the currency type and amounts mentioned in this Report are denominated in RMB.

This Report has undergone internal audit and review by the Board of Directors of the Company. The Board of Directors of the Group undertakes that this Report contains no false representations or misleading statements and assumes responsibility for the authenticity, accuracy, and completeness of its contents.

Access to the Report

This Report is published in both electronic and printed formats. It is available for download and review on the websites of the Shanghai Stock Exchange, the Singapore Exchange, or the official website of Da Ren Tang at www.jinyaodarentang.com.cn.



Contact Us

Tel: +86-022-27020892
Email: drt600329@163.com
Address: No. 17 Baidi Road, Nankai District, Tianjin, China.

Chairman's Statement



The year 2025 marks the conclusion of the "14th Five-Year Plan". The pharmaceutical industry is undergoing profound transformation and diversification, with challenges and opportunities coexisting. Over the past year, Da Ren Tang has advanced with determination through the dedicated efforts of all employees and, with the support of all stakeholders, has continued to pursue excellence. Upholding our core values of "Love, Quality, and Empowerment", we have maintained steady business growth while adhering to sustainable development, practicing green development principles, and striving to achieve harmony between corporate value and social well-being.

The Company has advanced the integrated development of "Brand Leadership and Community Public Welfare". During the Reporting Period, we officially launched the "Da Ren Tang Suxiao Jiuxin Public Welfare Initiative", establishing a benchmark for Da Ren Tang's public welfare brand. We successively carried out initiatives such as "Searching for Good 'Heart' People Across the Web", "First Aid Knowledge Training Camp", "Public 'Rescue' Assistance Stations", and the "Tibet Health for All" free medical consultation program. While contributing to the protection of national cardiovascular health, these initiatives further reinforced Da Ren Tang's brand positioning centered on "heart rescue". Our cultural promotion programs, including the "Guardian of Traditional Chinese Medicine Culture", "Traditional Chinese Medicine Culture on Campus", and the "Tianjin Traditional Chinese Medicine Cultural Fair", have reached the public both online and offline, significantly enhancing brand penetration. Through brand sponsorships and volunteer services, the Company actively participated in community activities such as the Tianjin Marathon, Tuanbo Lake Marathon, the SCO Tianjin Summit, the Summer Davos Forum, and the College Entrance Examination Support Program, achieving tangible results in both brand communication and community engagement.

The Company has advanced the dual drivers of "Quality Enhancement and User-Centricity". The achievements of Da Ren Tang's "Whole-Process Quality Traceability for Traditional Chinese Medicine" have been effectively implemented and were awarded the "2024 Quality Craftsmanship Achievement". In 2025, the Group completed extended GAP inspections for honeysuckle cultivation bases, established new traceability bases for *Pinellia ternata* under the "three none and one all" standard, as well as for *Gardenia* and 15 other varieties, and completed 35 GMP compliance inspections throughout the year. The Group also coordinated and promoted age-friendly revisions of package inserts for the first batch of six products and 71 packaging specifications in Tianjin, successfully launching them with integrated functions including "Digital Human Video + Electronic Leaflet + Voice Broadcast". The level of quality management across the entire industry chain, centered on consumers, has continued to advance. The Group completed Australian TGA certification for 2 sites and 4 dosage forms; NewScen Coast's HIV card-type colloidal gold reagent passed the on-site system audit for CE certification; 14 products were successfully registered in Singapore; 5 of our subsidiaries have obtained Indonesian International Halal Certification for 31 products; Angong Niu Huang Wan has officially received regulatory approval and is now commercially available in Macao. Quality improvement and product registration efforts have laid a solid foundation for enhancing product accessibility and improving user satisfaction. Da Ren Tang's "Whole Industry Chain Traceability" quality management model was awarded the Sixth Tianjin Quality Award (Grand Award).

The Company has coordinated the synergistic advancement of "Carbon Reduction and Cost Efficiency". Through systematic certifications, including Green Factory, Zero-Waste Factory, Carbon Footprint assessment, and ISO management systems, we have continuously enhanced our green governance capabilities. We have actively implemented green practices, including the construction of photovoltaic and small-scale wind power projects on the rooftop of the Da Ren Tang Building, the promotion of solar-powered streetlights and landscape lighting upgrades in factory parks, and the ongoing implementation of steam condensate recovery and reuse projects, as well as the conversion of medicinal residues into biomass fuel pellets. During the Reporting Period, the Company advanced centralized procurement of materials and optimized costs; strengthened lean management and established process control mechanisms for non-production materials to reduce losses; and promoted the transformation toward green manufacturing, achieving year-on-year reductions in energy and water consumption per unit of output value. This has realized the harmonious integration of economic benefits from lean management and the social benefits of green development.

The Company has adhered to the parallel advancement of "Employee Development and Organizational Enhancement". Through vocational skills competitions and labour contests, we have stimulated employee engagement and improved lean manufacturing capabilities. Through sports meets, Family Month activities, birthday celebrations, targeted assistance, and hardship support programs, we have enhanced employee well-being and continuously strengthened organizational cohesion. Through AI-themed training sessions and online cloud-based learning platforms, we have empowered employees across functions to enhance their professional skills. Through the establishment of the "Da Ren Tang Arts Troupe" and the "Da Ren Running Club", we have supported employees' personal interests and development. These efforts steadily promote the alignment between employees' self-realization and the Company's vision.

The year 2026 marks the beginning of the "15th Five-Year Plan". Da Ren Tang will focus on the "1+5" core work themes: centering on the brand leadership strategy while advancing scientific research and innovation, marketing transformation, operational excellence, organizational activation, and strategic synergy. We will comprehensively advance innovation across four dimensions: business innovation, product innovation, organizational innovation, and management innovation. While consolidating our core foundation, we will open new avenues for development. In the process of becoming a leader in modern traditional Chinese medicine, we will continue to enhance our performance in social, environmental, and governance dimensions in response to stakeholder expectations.

Thank you for your continued attention and support for Da Ren Tang.

Wang Lei
Chairman

About Da Ren Tang

Company Overview

Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd. is a national high-tech enterprise characterized by modern traditional Chinese medicine (TCM). At the same time, the Company possesses a profound historical legacy. It owns 4 "China Time-Honored Brand" enterprises—Da Ren Tang, Long Shun Rong, Le Ren Tang, and Jing Wan Hong, and holds 5 national-level intangible cultural heritage projects. The Company was listed in Singapore and Shanghai in 1997 and 2001 respectively, with its headquarters located in China. As an important member of the traditional Chinese medicine segment of Tianjin Pharmaceutical Group, the Company currently employs 3,890 staff members.

With traditional Chinese medicine as its core business, the Company's operations span the entire industry chain, including the cultivation and processing of medicinal materials, pharmaceutical research and development, manufacturing, and sales. In addition, the Company is engaged in chemical preparations, traditional Chinese medicine clinical services, retail, and the health and wellness sector.

12 Tianjin municipal-level intangible cultural heritage projects

Tianjin municipal-level intangible cultural heritage projects



5 National Intangible Cultural Heritage Items

- Traditional Production Technique of Qinggong Shoutao Wan of Da Ren Tang
- Traditional Production Technique of Angong Niu Huang Wan
- Traditional Production Technique of Niu Huang Qingxin Wan of Da Ren Tang
- Formulation and Production Technique of Jingwanhong Ointment
- Traditional Production Technique of Long Shun Rong Wei Medicines



The Company continues to focus on its core proprietary Chinese medicine business and consistently strengthens its core competitiveness in this area, forming notable advantages in both product scale and product portfolio structure. The Company currently holds 599 drug approval numbers, ranking among the leading enterprises in the industry, of which 122 are exclusive drug approval numbers. Its product portfolio covers multiple key therapeutic areas, including cardiovascular and cerebrovascular diseases, respiratory diseases, digestive system disorders, pediatrics, and dermatology. Several core products have been included in the National Essential Medicines List and the National Reimbursement Drug List. Certain products enjoy national protection for traditional Chinese medicine, national-level confidentiality status, or exclusive manufacturing qualifications, and are widely recognized in both clinical application and the marketplace. Relying on its profound heritage in traditional Chinese medicine and its modern pharmaceutical system, Tianjin Pharmaceutical Da Ren Tang continues to promote the standardization, industrialization, and high-quality development of traditional Chinese medicine.

The Company currently holds **599** drug approval numbers, ranking among the leading enterprises in the industry

of which **122** are exclusive drug approval numbers.


中华老字号
China Time-honored Brand

隆順裕® 達仁堂® 樂仁堂® 京万紅® 癩祺®

中国驰名商标



Suxiao Jiuxin Wan is the Company's flagship product. Since its launch more than forty years ago, it has consistently been committed to safeguarding national cardiovascular health, achieving coordinated development of economic value and social benefits. In 2025, the Company officially launched the "Da Ren Tang Suxiao Jiuxin Public Welfare Initiative", actively carrying out activities such as the "First Aid Knowledge Training Camp", "Public 'Rescue' Assistance Stations", and the "Tibet Health for All" free medical consultation program, thereby promoting the dissemination of cardiovascular emergency knowledge and improving access to diagnosis and treatment. The initiative was awarded the "Annual Public Welfare Innovation Award" and the "Annual Public Welfare Image Award".



Corporate Culture

Market-oriented
customer culture

Innovative culture
of seeking novelty and truth

Performance culture
of value contribution

Party-building culture
of spirit-casting cohesion

Professional culture
of continuous improvement

Talent culture of openness
and inclusiveness

Compliance culture
of respecting rules

Our Mission

Respecting and cherishing life,
spreading love

Core Values
Love, Quality,
and Empowerment

Corporate Spirit

Uphold righteousness,
innovate, and work together
for the greater good

Our Vision

To become a market-driven,
technology-empowered leader
in the health industry

The Outstanding Performance Highlights of Da Ren Tang in 2025

Upholding Benevolence and Strengthening Our Century-Old Foundation

Selected as a "2024 Best Practice in Investor Relations Management of Listed Companies" case
Awarded the "Tianma Award for Investor Relations Management of Chinese Listed Companies"
Number of litigation cases or major administrative penalties arising from unfair competition: 0

Adhering to Pharmaceutical Integrity and Forging the Quality of Da Ren Tang

Achieved the 2025 product quality and safety targets
Number of drug recall incidents: 0
Customer complaint closure rate: 100%
Number of data security and privacy breach incidents: 0

Following the Rhythm of Nature and Safeguarding Lucid Waters and Lush Mountains

Achieved the 2025 environmental-related targets
Annual energy savings in 2025 amounted to 66.76 tons of standard coal equivalent
Jingwanhong Pharmaceutical was awarded the national-level "Green Factory" title; No. 6 Chinese Medicine Plant, Long Shun Rong Pharmaceutical Factory, Le Ren Tang Pharmaceutical Factory, and Darentang Pharmaceutical Factory were awarded the "Green Factory" title by Tianjin Municipality
Jingwanhong Pharmaceutical, Medicinal Materials Company, and Le Ren Tang Pharmaceutical Factory were awarded the "Zero-Waste Factory" title by the Tianjin Municipality
No. 6 Chinese Medicine Plant was awarded the "Premium Zero-Waste Factory" title by the Tianjin Municipality

Advancing Social Benevolence and Creating Enduring Value

Products cover all provinces across China; exports extend to Singapore, Hong Kong, Macao, Japan, the Philippines, Indonesia, Malaysia, Canada, the United States, Russia, North Korea, and New Zealand, among other countries and regions
279 products are included in the National Reimbursement Drug List; 103 products are included in the National Essential Medicines List
Cumulative volunteer service hours: approximately 13,000 hours
Cumulative establishment of 2 GAP bases, 6 "three none and one all" bases, and 37 traceability bases
Led the formulation of 2 national standards

Inheriting Ancient Craftsmanship and Cultivating Talents of Shared Aspiration

Employee coverage of online learning platform: 100%
Total investment in employee training: RMB 4.2454 million
Employee training coverage rate: 100%; total training hours: 256,575 hours
Assisted more than 310 instances of employees in need, with a total assistance amount of RMB 750,000
Employee safety training coverage rate: 100%; number of major safety incidents: 0





China Association for Public Companies
2025 Typical Practice Case of the Board of Directors of Listed Companies



China Association for Public Companies
2025 Excellent Practice Case in Sustainable Development of Listed Companies



"The Edge Singapore"
Billion Dollar Club



Tianjin Municipal Science and Technology Bureau
Tianjin "Cheetah Enterprise"



Tianjin Municipal People's Government
Third Prize of Tianjin Science and Technology Progress Award (2024)



China Association of Traditional Chinese Medicine
Huatuo Traditional Chinese Medicine Award



China Association for Public Companies
Best Practice in Investor Relations Management of Listed Companies



Securities Times, People's Daily
16th China Listed Companies Investor Relations Management "Tianma Award"



E-Pharm Manager
2025 China Pharmaceutical Listed Companies ESG Competitiveness TOP 20



2025 Wuzhen Health Conference
West Lake Award · Top 10 Benchmark Enterprises in Pharmaceutical Manufacturing Digitalisation



Digital Intelligence Transformation and Innovation Selection Committee
2025 (8th) Digital Intelligence Transformation and Innovation Selection - Digital Marketing Benchmark Case



Third Future Pharmacy Development Conference
Outstanding Partner



12th County-Level Health Development Conference
County-Level Healthcare Excellence Empowerment Award



China Times
2025 Huaxia ESG "Dandelion" Typical Case



Tianjin Municipal People's Government
Tianjin Quality Award



China Pharmaceutical Quality Management Association
2024 Quality Management Craftsmanship Achievement



Meisi Conference
2025 Marketing Trend Award



Consumer Daily
2025 "High-Quality Recommended Product for Convenient Household Medicine Kit" in the Consumer Market



Annual Medical Conference Organising Committee;
Physician's Daily
2025 Top Ten Pharmaceutical Public Welfare Enterprises



All-China Federation of Trade Unions
Ministry of Emergency Management of the People's Republic of China
National Health Commission of the People's Republic of China
Outstanding Organizing Unit of the National "Ankang Cup" Competition

Statement from the Board of Directors

The Group fully recognizes the critical importance of sustainable development principles to the Company's steady and long-term development. We continue to establish and improve our sustainable development decision-making mechanisms and integrate them into our business operations and strategic planning.

As the decision-making body responsible for the Company's sustainable development, the Board of Directors pays close attention to sustainability-related risks and regularly reviews the Company's sustainability strategies and objectives. The management is responsible for promoting the implementation of various sustainability initiatives in day-to-day operations.

In 2025, considering our actual development conditions, we reassessed and adjusted the ESG factors that have a significant impact on the Company's development, reviewed the achievement of sustainability-related targets for 2025, and proposed key sustainability-related targets for 2026. In the field of sustainable development, we focus on environmental issues such as climate change, energy consumption, and waste management; prioritize social responsibilities, including product quality and safety, employee well-being, protection of customer rights and interests, and contributions to communities; and improve management systems related to responsible marketing and sustainability governance. In 2025, the Group achieved satisfactory results with respect to its sustainability-related targets.





Sustainability Governance Structure

To further enhance governance effectiveness and advance the Company's sustainable development, we have established and continuously improved our sustainability governance framework based on our practical situation. The Company has formulated the "Rules of Procedure of the Board Strategic and Sustainable Development Committee of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd." and the "Sustainable Development System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd", providing institutional support for decision-making, implementation, and supervision of sustainability initiatives.

To ensure professional management and effective implementation of sustainability initiatives, the Company has established a four-tier governance structure comprising the "Board of Directors — Strategic and Sustainable Development Committee— Sustainable Development Task Force — Sustainable Development Reporting Execution Team":



Da Ren Tang ESG governance structure

 Board of Directors	<p>As the highest decision-making body for the Company's sustainable development, the Board makes final decisions on major sustainability-related matters, ensuring a high degree of alignment between the Company's development direction and sustainability objectives.</p> <p style="text-align: right;">Decision-Making Level</p>
 Strategic and Sustainable Development Committee	<p>In 2025, the Company formally renamed the former "Strategy Committee" as the "Strategic and Sustainable Development Committee". The Committee is responsible for studying and formulating the Company's sustainability strategies, regularly reviewing and evaluating the Company's performance in fulfilling sustainability responsibilities, providing recommendations, and reporting to the Board of Directors.</p> <p style="text-align: right;">Management Level</p>
 Sustainable Development Task Force	<p>Serving as the routine liaison body of the Strategic and Sustainable Development Committee, the Working Group is responsible for coordinating and promoting the implementation of sustainability initiatives, integrating cross-departmental resources, and ensuring that sustainability strategies are translated into practical business actions. All senior executives and the Board Secretary are members of the Working Group, with the General Manager serving as the group leader.</p> <p style="text-align: right;">Management and Implementation Level</p>
 Sustainable Development Reporting Execution Team	<p>As the drafting body for the sustainability report, the Execution Group is responsible for summarizing and reporting on the Company's sustainability governance performance for the reporting period. The Board Secretary and heads of various departments serve as members, with the Board Secretary acting as group leader. The Securities and Investment Department serves as the coordinating department responsible for daily liaison, and the Audit Department is responsible for the internal assurance of the sustainability report.</p> <p style="text-align: right;">Reporting Level</p>

Looking ahead, we will continue to enhance the effectiveness and forward-looking nature of our sustainability governance system in response to changes in both internal and external environments, thereby supporting the Company in achieving its sustainability objectives.

ESG Capacity Building

To strengthen understanding and awareness of ESG, we continue to advance ESG capacity building within the Company. Through a combination of thematic training sessions and institutional learning, we reinforce relevant personnel's understanding of ESG principles, regulatory requirements, and professional topics.

In 2025, in response to the differing requirements and work priorities of management and execution levels, we organized 3 ESG thematic training sessions and learning workshops, providing systematic training and study on sustainability concepts, ESG information disclosure compliance requirements, and management practices. In addition, focusing on key ESG issues, the Company conducted multiple specialized training and exchange sessions in specific areas, promoting the integration of ESG requirements into concrete business and management scenarios. A cumulative total of 300 participant attendances was recorded, effectively enhancing the professional competence and performance capabilities of relevant personnel.



Stakeholder Engagement

The Company firmly believes that the core of sustainable development lies in effectively responding to stakeholders and continuously enhancing its capacity to create value for them. By establishing regular communication mechanisms, conducting industry collaboration, and engaging in government–enterprise dialogue, we proactively identify and respond to stakeholder expectations.

The Company's key stakeholders include groups that have a significant influence on the Group's operational decisions, business development, and long-term growth, or whose rights and interests may be materially affected by the Group's operating activities.

Stakeholder	Communication Channels	Key Concerns	Frequency
Government and Industry/ Standard Associations	<ul style="list-style-type: none"> Periodic reporting Regulatory study sessions Sustainability report Government policy communication meetings Questionnaires 	<ul style="list-style-type: none"> Industry regulations Environmental compliance 	<ul style="list-style-type: none"> More than 20 times per year
Investors and Shareholders	<ul style="list-style-type: none"> Annual report Investor relations activities General meetings of shareholders Questionnaires Results briefings Investor hotline and email 	<ul style="list-style-type: none"> Company financial performance Ensuring drug accessibility 	<ul style="list-style-type: none"> More than 100 times per year
Customers and Consumers	<ul style="list-style-type: none"> Annual report Product quality feedback (after-sales) Questionnaires In-store staff communication 	<ul style="list-style-type: none"> Product quality and safety Pharmaceutical certifications Compliance with Chinese health and safety laws and regulations Compliance with pharmaceutical marketing laws and regulations 	<ul style="list-style-type: none"> More than 100 participant attendances per year
Employees	<ul style="list-style-type: none"> Performance appraisal system Questionnaires Employee Representative Congress 	<ul style="list-style-type: none"> Employee health and safety Remuneration Benefits Compliance with Chinese labor laws and regulations 	<ul style="list-style-type: none"> Twice per year per employee
Suppliers	<ul style="list-style-type: none"> Supplier evaluations 	<ul style="list-style-type: none"> Product quality and compliance 	<ul style="list-style-type: none"> Annual periodic review
Communities	<ul style="list-style-type: none"> Community services Questionnaires 	<ul style="list-style-type: none"> Environmental impact Social development 	<ul style="list-style-type: none"> 10 times per year

Identification of Material Issues

In light of its actual development conditions and in accordance with the latest rules of the Singapore Exchange as well as the "Double Materiality" requirements set out in the *Self-Regulatory Guidelines No. 14 for Listed Companies – Sustainability Report (Trial)* issued by the Shanghai Stock Exchange, the Group conducted a materiality assessment of ESG issues from two dimensions: "financial materiality" and "impact materiality".

Review and Benchmarking

The Company conducted a systematic review of the 2024 Material Issues assessment results and related methodologies, and evaluated the coverage and boundaries of existing issues. The assessment concluded that the identified issues comprehensively reflect the core impacts and key concerns faced by the Company in its sustainable development.

Dynamic Identification and Assessment

Using the 21 issues listed in the Shanghai Stock Exchange guidelines as the foundational analytical framework, and considering annual operating conditions, business development priorities, external policy environment, rating requirements, and industry trend changes, we expanded and refined the scope of issues. Material issues were dynamically identified and assessed, with a focus on analyzing their degree of impact on the Company's operations, management, and medium- to long-term development.

Consolidation and Integration

Through expert discussions and internal evaluations, the Company consolidated and integrated certain issues with similar substance and highly overlapping management approaches, resulting in a total of 26 key issues, thereby further enhancing the clarity of the issue framework and the consistency of disclosures.

Review and Confirmation

Following discussion and review by the Company's management, the list of material issues for 2025 was formally confirmed. Eleven double materiality issues were assessed as material issues of high significance. In light of the Company's actual circumstances, corresponding targets were established for these 11 material issues of high significance.



1. Non-material topics are identified based on the Company's current dynamic assessment and evaluation, in combination with its existing operational practices and the prioritization results of the 26 key topics, and do not imply that these topics have no impact. This report also reviews and responds to 6 non-material topics.

Due Diligence

The Company has systematically carried out ESG due diligence. For the 11 identified material issues of high significance, the Company has identified and assessed the related impacts, risks, and opportunities, and has effectively managed adverse impacts and risk points, as set out in the table below. For each issue, corresponding management measures have been implemented, which are detailed in the relevant sections of this Report.

Major Material Issues	Risks and Impacts	Key Opportunities	Value Chain Segment Affected	Relevant Management Section
Compliance and Risk Control	<p>Actual positive impact: The Company has established an internal compliance system and, by standardizing contract, procurement, and sales processes, has enhanced transaction transparency and traceability, effectively reducing the occurrence of non-compliance incidents.</p> <p>Potential negative impact: Involvement in violations may result in regulatory penalties, fines, or legal proceedings.</p>	<p>Market opportunity: A sound compliance management system enhances trust from regulators and the market, improves cooperation and convenience with suppliers, distributors, and partners, and creates conditions for strategic expansion and steady business development.</p>	<p>Upstream value chain; Own operations; Downstream value chain</p>	Compliance and Risk Control Enhancement
Product Quality and Safety	<p>Actual positive impact: Through the establishment of a digitalized "Whole Industry Chain Traceability for Traditional Chinese Medicine" quality management model and a three-tier quality management system at the Group level, the Company ensures product quality and safety and the fulfillment of corporate responsibility, thereby enhancing the market recognition and competitiveness of the "Da Ren Tang" brand.</p> <p>Potential negative impact: Under the digitalized traceability model, quality control requirements extend from traditional production compliance to upstream supplier quality capability building and downstream responsiveness to personalized consumer needs, placing higher demands on coordinated management across the entire industry chain. Insufficient capabilities in supplier quality control, data integration, and full-process coordination may amplify quality risks, affect product safety and stability, and adversely impact brand reputation and market trust.</p>	<p>Market and brand opportunity: High-quality products and a safety reputation facilitate domestic and international market expansion, increase export licenses and registration opportunities, enhance patient and consumer trust, and support product differentiation and brand premium capability.</p>	<p>Upstream value chain; Own operations; Downstream value chain</p>	Quality and Safety Assurance
Resource Management	<p>Actual positive impact: Through water-saving, energy-saving, and material optimization measures, the Company has improved resource utilization efficiency, enhanced supply chain resilience, and reduced production costs.</p> <p>Potential negative impact: High dependence on water and raw materials with low resource efficiency may lead to rising costs, resource constraints, and environmental and compliance pressures.</p>	<p>Policy and cost opportunity: Efficient resource management aligns with green production policies and may obtain policy incentives, including tax benefits, green financing, and subsidies, while enhancing supply chain resilience and ensuring the supply of key raw materials.</p>	<p>Upstream value chain; Own operations</p>	Green Operations Implementation
Waste Management	<p>Actual positive impact: The Company has implemented waste classification and standardized disposal measures, effectively reducing environmental risks and improving environmental management performance.</p> <p>Potential negative impact: Improper disposal of hazardous waste or TCM residues may lead to environmental pollution, regulatory penalties, and community complaints, affecting corporate reputation and operational stability.</p>	<p>Policy and brand opportunity: Resource utilization of waste can create economic and environmental value while enhancing the corporate social responsibility image and public recognition.</p>	<p>Own operations; Downstream value chain</p>	Green Operations Implementation
Employee Rights and Compensation	<p>Actual positive impact: The establishment of a competitive remuneration and benefits system, combined with diversified employee care initiatives, effectively enhances employee satisfaction and sense of belonging, strengthening team cohesion and productivity.</p> <p>Potential negative impact: If remuneration and benefits are not aligned with industry or market developments, talent retention and team stability may be affected, requiring ongoing evaluation and dynamic adjustment.</p>	<p>Talent and brand opportunity: A comprehensive employee rights and remuneration system helps attract and retain key talent, supports technological innovation and efficient operations, and enhances employer brand competitiveness.</p>	<p>Own operations</p>	Employee Rights and Compensation

Major Material Issues	Risks and Impacts	Key Opportunities	Value Chain Segment Affected	Relevant Management Section
Energy Management	<p>Actual positive impact: Through energy-saving upgrades and monitoring measures, the Company has reduced energy consumption per unit of product and production costs, improving energy efficiency.</p> <p>Potential negative impact: Excessive energy consumption may increase production costs and carbon compliance costs; energy supply fluctuations may affect production continuity.</p>	<p>Policy and cost opportunity: Optimizing energy structure and improving energy efficiency reduces operating costs and enables the use of green financial tools and carbon reduction policies to enhance corporate green image and market recognition.</p>	Upstream value chain; Own operations	Green Operations Implementation
Occupational Health and Safety	<p>Actual positive impact: The Company has established safety management systems and protective measures, reduced accident rates, implemented health management systems, conducted inspections, training, and emergency drills, safeguarded employees' health, and ensured production safety and employee well-being.</p> <p>Potential negative impact: Inadequate management during production and laboratory processes may lead to occupational injuries and diseases, resulting in legal liabilities, production suspensions, and reputational losses.</p>	<p>Brand opportunity: A sound occupational health and safety management system reduces accident rates, safeguards employee safety, and enhances internal management standards and employer image.</p>	Own operations	Employee Safety Assurance
Emission of Pollutants	<p>Actual positive impact: Through control and monitoring of wastewater, exhaust gas, and noise emissions, the Company reduces environmental non-compliance risks, improves environmental performance, and ensures compliant production.</p> <p>Potential negative impact: Excessive emissions may lead to environmental incidents, regulatory penalties, and community complaints, adversely affecting reputation and operations.</p>	<p>Policy and brand opportunity: Strict emission management enables early adaptation to more stringent environmental regulations, reduces policy risks, enhances green production recognition, and supports expansion into high-end markets and access to policy incentives.</p>	Own operations; Downstream value chain	Environmental Compliance Management
Environmental Compliance Management	<p>Actual positive impact: The Company has established an environmental management system to ensure compliance in production processes, reducing legal risks and enhancing operational stability.</p> <p>Potential negative impact: Failure to update environmental management measures or comply with regulatory requirements may result in administrative penalties or production restrictions.</p>	<p>Policy opportunity: Institutionalized environmental compliance management reduces legal risks and facilitates early adaptation to policy changes, creating opportunities for green projects and investments.</p>	Own operations	Environmental Compliance Management
Addressing Climate Change	<p>Actual positive impact: Through climate risk assessment and energy structure optimization, the Company enhances risk identification capability, reduces potential policy costs, and strengthens supply chain resilience and operational stability.</p> <p>Potential negative impact: Extreme weather events may affect raw material supply and production continuity. The Company has been included in Tianjin's 2025 key carbon emission units list and is subject to quota management; carbon pricing and trading policies may increase operating costs.</p>	<p>Policy and market opportunity: Proactive climate risk identification and response help optimize energy structure and production layout, enhancing long-term resilience and sustainable competitiveness.</p>	Upstream value chain; Own operations; Downstream value chain	Climate Change Response
Employee Training and Development	<p>Actual positive impact: The Company has established a systematic training system and career development pathways, continuously enhancing employees' professional capabilities and job adaptability, thereby strengthening organizational effectiveness and talent loyalty.</p> <p>Potential negative impact: If training investment and development mechanisms do not align with business development needs, organizational capability enhancement may be affected, requiring regular evaluation and system optimization.</p>	<p>Talent and innovation opportunity: Systematic training supports technological innovation, quality management, and compliance execution, enhances employer brand value, and supports strategic objectives in high-end business expansion and technological innovation.</p>	Own operations	Employee Training and Development

Da Ren Tang adheres to the development philosophy of "preserving the essence and pursuing integrity-driven innovation", regarding intangible cultural heritage techniques as important cultural assets and core competitive strengths. In the context of the new era, we promote the integration of traditional Chinese medicine culture with modern industrial development, and have explored and formed an implementation pathway that leverages intangible cultural heritage inheritance to strengthen cultural confidence, utilizes brand development to serve public health, and supports sustainable development through innovative practices. Through these efforts, we continuously enhance the cultural connotation and social recognition of our brand, demonstrating responsibility and commitment in promoting traditional Chinese medicine culture and safeguarding public health.

Upholding Intangible Cultural Heritage Roots and Inheriting the Wisdom of Traditional Chinese Medicine

The path of traditional Chinese medicine embodies benevolence in practice. Since its establishment, Da Ren Tang has been committed to continuously improving a traditional Chinese medicine protection system centered on intangible cultural heritage. As of the end of 2025, the Group holds a total of 5 national-level representative intangible cultural heritage projects and 12 municipal-level intangible cultural heritage projects in Tianjin, covering key stages including traditional Chinese medicine processing, formula development, and large-scale production.

As of the end of 2025

the Group holds a total of **5** national-level representative intangible cultural heritage projects



and **12** municipal-level intangible cultural heritage projects in Tianjin.

In terms of the protection and application of intangible cultural heritage techniques, the Group adheres to integrity as the foundation and implements full-process technical control over national-level intangible cultural heritage projects such as the Traditional production techniques of Qinggong Shoutao Wan and Niuhuang Qingxin Wan. We strictly follow the traditional principle that "no matter how complex the processing, manual craftsmanship shall never be spared", and have established a full-process traceability system covering medicinal material cultivation, production, and processing, and product release. In addition, in combination with modern pharmacological research and quality management requirements, we continuously verify the safety and efficacy of core techniques.

With respect to talent cultivation for heritage inheritance, Da Ren Tang continues to explore diversified pathways for the transmission of intangible cultural heritage. Through the traditional master-apprentice model, combined with external exchanges, academic collaborations, and experiential practice, we promote the intergenerational continuity and living transmission of traditional Chinese medicine intangible cultural heritage techniques. Meanwhile, we have established cultural communication platforms such as the Da Ren Tang Traditional Chinese Medicine Culture Exhibition Hall. Through initiatives including traditional Chinese medicine culture entering campuses, intangible cultural heritage experience programs, and public health education activities, we continuously expand social participation and public awareness of intangible cultural heritage during its transmission.

500 辉煌史 成就新国药

Five Centuries of Heritage, Building a Modern National Pharmaceutical Brand

1522

The Le family relocated to Beijing.

1684

Le Xianyang standardized pharmacy operations.

1833

Bian Chufang founded Long Shun Rong Pharmacy.

Case "Rising Tides in Tianjin · National Heritage Wellness" Tianjin Traditional Chinese Medicine Cultural Fair

Sponsored by Da Ren Tang Group, Tianjin's first "Rising Tides in Tianjin · National Heritage Wellness" Traditional Chinese Medicine Cultural Fair has, since its launch, continuously promoted the integration of traditional Chinese medicine culture into citizens' daily lives. The program integrates intangible cultural heritage displays, health services, and lifestyle-oriented wellness experiences, establishing a benchmark platform for the deep integration of "traditional Chinese medicine culture + public-benefit services + cultural and tourism industries". As of the end of November 2025, the event had been held 13 times across all 16 districts of the city, attracting nearly one million cumulative participants and effectively enhancing public awareness of traditional Chinese medicine culture and accessibility to health services.

At the fair, Da Ren Tang's "beverage + dietary" wellness system, centered on medicinal pastes, herbal teas, and herbal-infused bakery products, was widely welcomed. Youth-oriented products such as traditional Chinese medicine coffee, portable tea sachets, and herbal sunscreen, as well as intangible cultural heritage showcases of time-honored brands including Jing Wan Hong and Le Ren Tang, became popular attractions among younger visitors.



2022



1955

Da Ren Tang completed public-private partnership reform.

1915

Le Daren founded Darentang Pharmaceutical Factory.

1921

Le Youshen founded Le Ren Tang.

1997&2001

Listed in Singapore and Shanghai.

Advancing Digital Innovation and Revitalizing the Time-Honored Brand

In response to the challenges of the digital era, Da Ren Tang has actively promoted digital and intelligent transformation, building a dual-core framework of "Data + AI". Focusing on key business scenarios including marketing, research and development, intelligent manufacturing, and medicinal material resources, the Company has comprehensively advanced the implementation of digital applications, achieving deep integration between technological empowerment and traditional heritage, and enabling the century-old time-honored brand to rejuvenate in the digital age.

In 2025, Da Ren Tang officially initiated its AI deployment and implemented a series of strategic planning and implementation measures:

- The Company signed a comprehensive cooperation agreement with Huawei. The jointly declared "Artificial Intelligence + Multi-Scenario Applications in Traditional Chinese Medicine" project received digital incentive support for high-quality development from Tianjin Municipality and became the only pharmaceutical enterprise awarded in the AI application category of the program.
- In collaboration with Huawei's expert team, the Company focused on 16 high-priority and high-value scenarios across five major business domains—medicinal material resources, supply chain, research and development, marketing, and operations—for systematic discussion and planning. By the end of 2025, priority implementation had been advanced in selected scenarios within the supply chain and marketing domains.
- The Da Ren Tang Retail Momentum Cockpit is a self-developed marketing intelligence platform (marketing data analysis and insight platform). Based on robotic process automation and AI large models, it realizes full-process automated collection, processing, and analysis of marketing data. The efficiency of data insight and business strategy generation has increased tenfold, forming a closed-loop marketing digital intelligence system integrating data insights, strategy output, and human-machine collaboration. The project was recognized as a typical case of enterprise-level AI application implementation in 2025.
- The Da Ren Tang AI Super Content Factory is a self-developed, one-stop multi-agent platform for content creation, distribution, and management. It empowers high-value scenarios such as health education, marketing posters, and packaging design, achieving systematic content creation and precise distribution, and building a "direct-to-consumer" content productivity system. The project has received multiple national and industry digital marketing innovation awards and was selected as a benchmark case under the "Data × AI" scenario category.

Expanding International Communication and Telling China's Intangible Cultural Heritage Story

Rooted in the essence of outstanding traditional Chinese culture, Da Ren Tang actively expands international communication channels and promotes the global narrative of China's intangible cultural heritage and traditional Chinese medicine culture. Through participation in international forums, commercial exhibitions, and cultural exchange activities, the Company continuously enhances its international brand influence and cultural recognition, contributing to the acceleration of traditional Chinese medicine culture's global outreach.

In 2025, we actively engaged in international exchanges. At the 8th Belt and Road Forum on the Development of Traditional Chinese Medicine, the Company participated as a representative enterprise of the industry and showcased its representative products and innovative achievements. Through this international exchange platform, we engaged with representatives from government, industry, and academic institutions to jointly explore pathways for the internationalization of traditional Chinese medicine and enhance the visibility and recognition of traditional Chinese medicine brands in global exchanges.

Case Tianjin Pharmaceutical Da Ren Tang Supporting the Dissemination of Traditional Chinese Medicine Culture at the Shanghai Cooperation Organization Tianjin Summit

During the 2025 Shanghai Cooperation Organization Tianjin Summit, Da Ren Tang, as the official supporting unit for summer health and wellness supplies, established a traditional Chinese medicine health service area in the intangible cultural heritage exhibition zone of the Summit Media Center. Centered on traditional Chinese medicine intangible cultural heritage, and integrating traditional Chinese medicine therapy, herbal wellness, and modern health concepts, the Company provided immersive traditional Chinese medicine cultural experiences for domestic and international guests.

The Group organized professional medical and service teams and implemented a round-the-clock support mechanism, providing services including traditional pulse diagnosis, acupoint massage, and medicinal and dietary wellness beverages. During the Summit, more than 3,000 domestic and international journalists and guests were served. These practices received positive recognition from international media, effectively enhancing the international perceptibility of traditional Chinese medicine culture and making a positive contribution to its global dissemination.



Case Da Ren Tang Showcases Traditional Chinese Medicine Culture and Health Services at the Tianjin Summer Davos Forum

During the 2025 Tianjin Summer Davos Forum, Da Ren Tang centered its efforts on the integration of traditional Chinese medicine (TCM) intangible cultural heritage and modern technology, carrying out TCM cultural exhibitions and health service initiatives. We carefully established a cultural exhibition platform featuring classic products such as Angong Niu Huang Wan, sachet-making activities, and traditional incense cultural and creative experiences, transforming the concept of "preventive treatment of disease" into cultural content that is observable, experiential, and participatory, thereby enhancing international guests' cultural understanding. At the same time, we organized a team of TCM experts to provide health consultations and specialized therapeutic massage services, and showcased the "Smart Traditional Chinese Medicine Diagnosis and Treatment System" to distinguished guests from various countries, establishing a multidimensional new paradigm for the international dissemination of traditional Chinese medicine.



Empowering the Brand through Public Welfare and Practicing the Philosophy of benefiting people's livelihood

In its brand communication practices, Da Ren Tang adheres to a people-oriented approach centered on public health needs, deeply integrating the value philosophy of traditional Chinese medicine with social responsibility. The Company continuously carries out public health initiatives, guiding the public toward scientific health awareness and promoting the extension of brand communication from image presentation to social value creation. In 2025, in response to social public health challenges such as the high incidence and increasing prevalence of cardiovascular and cerebrovascular diseases among younger populations, we leveraged long-term public welfare practices and, in collaboration with JD Health, China's 120 Emergency Center, the China Chest Pain Center, and hundreds of chain institutions, jointly launched the "Da Ren Tang Suxiao Jiuxin Public Welfare Initiative". From three dimensions—emergency response support, health management, and social advocacy—we systematically advanced cardiovascular health public welfare practices, actively contributing to the implementation of the "Healthy China" strategy.

- In terms of emergency response support, to enhance the emergency handling capacity for sudden cardiovascular events, we donated Suxiao Jiuxin Wan to **83,000** AED rescue stations nationwide, and donated **500,000** early screening test kits for myocardial infarction to more than **100** chain institutions. Concurrently, we conducted rescuer training programs, with more than **20,000** participants in the first phase, and provided supporting donations of AED equipment, thereby contributing to the allocation and capacity enhancement of grassroots emergency response resources in China.



we donated Suxiao Jiuxin Wan to **83,000** AED rescue stations nationwide

donated **500,000** early screening test kits for myocardial infarction to more than **100** chain institutions

Concurrently, we conducted rescuer training programs, with more than **20,000** participants in the first phase



- In terms of health management, we fully leverage the traditional Chinese medicine concept of preventive treatment of disease, shifting from a treatment-centered approach to a whole-lifecycle health management model centered on prevention, emergency response, treatment, and rehabilitation. In collaboration with **100** authoritative hospitals and **200** experts in the field of cardiovascular medicine, we jointly released the *2025 White Paper on Cardiovascular Health of the Chinese Population*. To date, **26,000** copies have been distributed to the public free of charge, systematically disseminating knowledge on the prevention, treatment, and health management of cardiovascular diseases, promoting the extension of public welfare initiatives into communities and rural areas, and bridging the "last mile" of health management services.



- In terms of social advocacy, we initiated public welfare communication campaigns such as "Searching for Good 'Heart' People Across the Web" through our brand communication platforms, continuously promoting the positive social values of mutual assistance and emergency support. The campaign reached an accumulated audience of approximately **400** million person-times. Through the dissemination of real-life rescue stories, it guided the public to pay attention to emergency response knowledge, respect the value of life, and foster a positive and benevolent social atmosphere.



01 Upholding Benevolence and Strengthening Our Century-Old Foundation

Prudent Corporate Operations	29
Compliance and Risk Control Enhancement	34
Business Ethics Adherence	36



Corporate Governance Compliance and Risk Control

Responsible Marketing Anti-Bribery and Anti-Corruption Anti-Monopoly and Fair Competition

Da Ren Tang adheres to standardized governance as the foundation of its sustainable development. Focusing on key areas including Board governance, compliant operations, risk control, and business ethics, the Company clarifies the boundaries of rights and responsibilities, strengthens institutional implementation, and promotes the deep integration of governance requirements with operational management, thereby providing a solid safeguard for prudent operations and long-term value creation.




Corporate Governance

The Group has established a corporate governance structure comprising the General Meeting of Shareholders, the Board of Directors, specialized committees, and the senior management team. We operate in strict compliance with the *Company Law of the People's Republic of China*, the *Securities Law of the People's Republic of China*, *Listing Rule 711B*, and other applicable laws and regulations of China and Singapore, as well as the rules of the relevant stock exchanges. The Board of Directors has established the Audit Committee, the Compensation and Appraisal Committee, the Nomination Committee, and the Strategic and Sustainable Development Committee, each responsible for the management of specific matters. In 2025, the Company reviewed and approved the proposal to amend the "Articles of Association", abolishing the Supervisory Board and transferring its functions to the Audit Committee of the Board of Directors, thereby further optimizing the governance structure and enhancing the efficiency of supervision and decision-making coordination.

In 2025, the specialized committees convened as follows: the Audit Committee held 5 meetings; the Strategic and Sustainable Development Committee held 1 meeting; the Compensation and Appraisal Committee held 1 meeting; and the Nomination Committee held 1 meeting.

In 2025, the specialized committees convened as follows:



We have formulated and convened General Meetings of Shareholders and meetings of the Board of Directors in accordance with the "Rules of Procedure for the General Meetings of Shareholders of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", the "Rules of Procedure for the Board of Directors of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", and the "Independent Directors System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.". In 2025, the Company convened 1 annual General Meeting of Shareholders, 2 extraordinary General Meetings of Shareholders, and 6 Board meetings, with a 100% attendance rate for Board meetings.



2024 Shareholders' Meeting

The Company adheres to the principles of professionalism, diversity, and internationalization, comprehensively enhancing the quality of Board decision-making and operational effectiveness. As of the end of the Reporting Period, the Board comprised 9 directors, including 3 executive directors, 3 non-executive directors, and 3 independent directors, among whom 2 were female directors. All three independent directors are Singapore nationals and serve as chairpersons or members of the respective specialized committees of the Board. The Audit Committee is composed entirely of independent directors. Meanwhile, the directors possess diverse professional backgrounds and experience in pharmaceuticals, investment, management, finance, and other fields. The complementary expertise and skill sets of each director ensure the scientific and rational nature of the Board's decision-making.

In 2025



the Company convened **1** annual General Meeting of Shareholders

2 extraordinary General Meetings of Shareholders

6 Board meetings



with a **100%** attendance rate for Board meetings

As of the end of the Reporting Period



the Board comprised **9** directors

including **3** executive directors, non-executive directors, independent directors


among whom **2** were female directors

Investor rights protection

Da Ren Tang consistently attaches great importance to the protection of investors' rights and interests. The Company has established the "Investor Relations Management System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd." and the "Information Disclosure Management System". We strictly comply with regulatory requirements in both China and Singapore, continuously strengthen information disclosure and insider information management, and adhere to prudent and stringent disclosure principles to ensure consistency between domestic and overseas disclosures, as well as the authenticity, accuracy, timeliness, and completeness of information.

We have established diversified communication channels and methods. Through the Company's official website and new media platforms, we publish annual reports, quarterly reports, and announcements of significant matters, enabling investors to access information conveniently at any time. Dedicated investor hotlines and email addresses have been set up, and results briefings are regularly held to promptly respond to investor concerns. In 2025, with respect to four periodic reports, we organized 3 results briefings. We also conducted regular investor communication meetings, institutional research receptions, and strategy meetings, and continuously responded to investor inquiries through the SSE E-Interaction platform, telephone, and email.


In terms of deepening communication formats, during General Meetings of Shareholders, the Company organized activities such as health product tasting sessions, free medical consultations for shareholders, and visits to the Da Ren Tang Museum. We also continued to conduct the "Seasonal Wellness — Shareholders Visiting Da Ren Tang" series of activities, inviting shareholders to visit the museum and production facilities to experience traditional Chinese medicine intangible cultural heritage techniques, thereby enhancing investors' understanding of the Company's business and culture.



Shareholder Visit activity

In 2025, the Company was selected as a "2024 Best Practice in Investor Relations Management of Listed Companies" case by the China Association for Public Companies and was awarded the "China Listed Companies Investor Relations Management Tianma Award" at the 16th Tianma Awards organized by *Securities Times*.

We attach great importance to shareholder returns and have compiled statistics on dividend distributions to shareholders over the past three years, as shown in the figure below:



In 2025, the Company implemented the 2024 Annual Equity Distribution Plan, distributing a cash dividend of RMB 12.80 (tax inclusive) for every 10 shares to all shareholders. In addition, the "proposal on the profit distribution plan for the first three quarters of 2025" was reviewed and approved, under which a cash dividend of RMB 24.50 (tax inclusive) per 10 shares is proposed to be distributed to all shareholders.

Party Building Leadership

Enhancement of Party Organization Development

Da Ren Tang continues to improve its Party organizational structure, promoting the deep integration of Party-building work with the corporate governance system. As of the end of the Reporting Period, the Group had established 5 Party committees, 2 general Party branches, and 43 Party branches, covering all business segments and key production and operational units, with a total of 940 Party members. This structure further strengthens the leadership role of Party organizations and provides strong organizational support for standardized governance and prudent development.

With Party-building brand development as a focal point, the Company promotes the deep integration of Party-building initiatives with its core operations, leveraging high-quality Party-building to drive high-quality development. In 2025, the Group was recognized with 9 outstanding Party-building brand cases and newly applied for 3 additional Party-building brand cases, gradually forming a Party-building model with distinctive Da Ren Tang characteristics.

Ideological Education Enhancement

The Company continues to strengthen the development and capability enhancement of Party members. Through thematic study sessions, seminars, joint branch activities, and other initiatives, all Party members are guided to deepen theoretical learning and closely integrate theory with practice. In 2025, considering the characteristics of the traditional Chinese medicine industry and specific job functions, the Group organized systematic training programs covering four modules: Party history and discipline education, development of the traditional Chinese medicine industry, cultivation of Party member competence, and red-themed film viewing. Through a combination of online and offline approaches, Party members were guided to continuously enhance their political literacy and professional capabilities, and to translate learning outcomes into practical application in their respective roles.



Red-themed movie-watching Party Day activity



A Party lecture on thoroughly implementing the spirit of the Central Committee's Eight-Point Regulation.

Case Collective Viewing of the 80th Anniversary Commemoration of the Victory of the Chinese People's War of Resistance and the World Anti-Fascist War

On 3 September 2025, the Party Committee of Da Ren Tang Group organized 12 affiliated enterprises, including the Modern Traditional Chinese Medicine Industrial Park, No. 6 Chinese Medicine Plant, and Le Ren Tang Pharmaceutical Factory, to participate in a collective viewing of the commemorative event marking the 80th anniversary of the victory of the Chinese People's War of Resistance Against Japanese Aggression and the World Anti-Fascist War. Members of the Company's Party and the administrative leadership team, as well as the Chief Technical Expert, took part in the activity. Through collectively watching the military parade and important speeches, Party members and cadres further deepened their understanding of the spirit of the War of Resistance and the nation's historical journey of struggle, strengthened historical awareness and sense of mission, and promoted the substantive implementation of patriotism education and education on ideals and convictions within the Company.



Integration of Party Building and Business Operations

Da Ren Tang is committed to promoting the deep integration of Party-building initiatives with business operations, transforming Party-building resources into development advantages and realizing the synergy of "Party building promoting business and coordinated development". Since the launch of the "Chinese Heart · Healthy Journey" joint Party branch initiative in June 2022, Party branches under the Group have conducted a total of 117 joint activities and established stable cooperative relationships with 92 external Party branches.

In 2025, the Group carried out 20 joint activities, with the scope of collaboration gradually expanding to multiple provinces and cities, including Henan, Qingdao, Hunan, Shenyang, and Shanghai. Party organizations at all levels of the Group, aligned with the Company's strategic direction and market orientation, organized thematic research, exchange, and practical activities through joint themed Party days, public health education initiatives, and visits to terminal markets. These efforts guided Party members and Party affairs personnel to deepen their understanding of the Company's development pathway through market research, experience sharing, and management improvement, further strengthening the supportive role of Party-building work in business decision-making and execution.

Since the launch joint construction activities, Party branches under the Group have conducted a total of

117 joint activities

and established stable cooperative relationships with

92 external Party branches

In 2025, the Group carried out

20 joint activities

Case "Breakthrough — Either the Only One or the First" Thematic Research and Exchange Activity

In 2025, Da Ren Tang organized the special initiative titled "Breakthrough — Either the Only One or the First", bringing together Party affairs personnel and outstanding Party member representatives to participate in a three-day research and exchange program comprising four components: attending Party lectures, conducting market research, sharing experiences, and visiting red education bases. By engaging deeply at the frontline to address business challenges, the initiative translated red cultural heritage into practical momentum for innovation and breakthrough, achieving dual empowerment of Party building and market expansion, as well as problem-solving.



Compliance and Risk Control Enhancement

Compliance and Risk Control

Governance

We strictly comply with applicable laws and regulations and continuously strengthen our compliance and risk management system. The Company has formulated normative institutional documents, including the "Compliance Management Measures of Tianjin Pharmaceutical Da Ren Tang Group" and the "Compliance Risk Assessment Rules of Tianjin Pharmaceutical Da Ren Tang Group", and has established a comprehensive mechanism for the identification, assessment, and response to compliance risks. The Company has constructed and operated a "three lines of defense" compliance risk management framework, clearly defining the responsibilities at each level, embedding compliance requirements throughout the entire process of business operations and management, and continuously enhancing the effectiveness and execution of compliance management. The Company has obtained ISO 37301:2021 Compliance Management System certification.



Three Lines of Defense for Compliance Risk Management:

First Line of Defense: Specific business departments, responsible for proactively identifying compliance risks within their respective business activities, issuing compliance risk alerts, formulating compliance risk prevention and control measures, and managing compliance risks at the operational level.

Second Line of Defense: The compliance management department (Legal and Compliance Department) responsible for organizing, coordinating, and supervising compliance management work, providing compliance support to other departments, and conducting legal and compliance reviews of major matters, including significant decision-making and major contract execution.

Third Line of Defense: Compliance supervision departments such as the Discipline Inspection and Supervision Office and the Audit Department, which perform oversight, auditing, and supervisory duties within their respective scopes of responsibility in relation to compliance management.

Strategy

We deeply integrate compliance and risk control management into our medium- and long-term governance strategy and steadily advance the full life-cycle development of the compliance system. In 2025, the Company entered a key phase of "deepening and upgrading" compliance management, focusing on areas such as marketing compliance management, digitalization of promotional evidence, management of promotional service providers, and compliance training, thereby continuously enhancing the systematic and refined level of compliance management.

Impact, Risk, and Opportunity Management

Compliance Risk Management

The Company has established and operates a full-process compliance risk management mechanism covering risk identification, assessment, response, monitoring, early warning, and reporting. The Legal and Compliance Department takes the lead in coordination, with business and functional departments collaborating in implementation, forming a clearly defined and dynamically updated closed-loop compliance risk management framework. Considering the regulatory environment and operational characteristics of the pharmaceutical industry, we conduct regular compliance risk assessments, focusing on high-risk business activities, expense management, and contract management. Through such assessments, potential compliance risks are identified, and early warnings are issued promptly, thereby safeguarding the Company's compliant operations.

In 2025, we continued to strengthen the compliance training system, implementing tiered and categorized compliance training for management, key business personnel, and frontline employees. These efforts promote the integration of compliance principles into daily operations and effectively enhance employees' compliance awareness and behavioral standards.



Internal Control and Risk Management

The Company proactively identifies and mitigates risks and has established an internal control system based on the COSO Internal Control Framework. We have developed an internal control and risk management system covering various business and management processes, continuously identifying, assessing, monitoring, and improving key risks. At the same time, we have established a standardized internal audit workflow that is business-based and risk-oriented. On this basis, we continuously expand audit procedures, emphasize key audit priorities, and promote the Company's sustained and sound development.

The Company has formulated the "Internal Audit System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", promptly evaluating the effectiveness of internal control operations and continuously improving the internal control framework. In 2025, in accordance with the "Guidelines for the Application of Enterprise Internal Control", we organized 12 affiliated enterprises to conduct internal control self-assessments, covering key business modules including procurement, sales, fund management, and contract management, thereby continuously enhancing internal control effectiveness.

Tax Compliance

The Company strictly complies with national laws and regulations, fulfills its tax obligations in accordance with the law, continuously improves its tax compliance management system, strengthens tax risk prevention and control capabilities, and ensures that all taxes are paid lawfully, in full, and promptly.

In 2025, focusing on the standardization and refinement of tax management, the Company continued to advance the digitalization of tax management, completing digital tax management implementation across all 29 subsidiaries. This enabled automated data extraction, filing support, and compliance analysis for major taxes, including value-added tax, stamp duty, and corporate income tax prepayments, improving the accuracy of reconciliation between tax and financial data and effectively reducing tax compliance risks.

Indicators and Targets

During the Reporting Period, we actively promoted the coverage of compliance management across key business areas and critical processes, enhancing the systematic nature and effectiveness of compliance and risk control. No major compliance risk incidents occurred during the year.

Our annual targets and progress are as follows:

FY2025 Target	FY2025 Progress
Zero incidents of non-compliance in product marketing and labeling	Strict implementation of marketing management systems, standards, and procedures; continuous improvement of existing policies and processes in accordance with the latest marketing compliance laws and regulations.
FY2026 Target	Planned Actions
Zero incidents of non-compliance in product marketing and labeling	Based on consolidating the existing system, promote the evolution of compliance management toward a more intelligent, proactive, and in-depth approach.

Business Ethics Adherence

Anti-Bribery and Anti-Corruption

Management System Enhancement

Da Ren Tang strictly upholds the bottom line of integrity in professional conduct and implements a zero-tolerance policy toward commercial bribery and corruption. Through institutional development, education and communication, and supervisory management, we have established a comprehensive and multi-tiered anti-bribery and anti-corruption system. We have formulated and promulgated the "Integrity in Professional Conduct Management Provisions of Tianjin Pharmaceutical Da Ren Tang Group", applicable to all employees, providing clear standards and guidelines for employee conduct and ensuring that integrity in professional conduct is governed by established rules.

For long-term and key suppliers, we require suppliers to sign the "Integrity Cooperation Agreement" and the "Confidentiality Agreement", and incorporate social responsibility clauses into procurement contracts. Compliance operations, business ethics, and responsible performance requirements are embedded throughout the entire cooperation cycle, promoting stable and mutually trusting collaborative relationships across the value chain.

The Discipline Inspection and Supervision Office of the Group serves as the core executive body for disciplinary inspection and supervision, comprehensively responsible for disciplinary and supervisory affairs across the Company and exercising oversight over all employees to strengthen the integrity safeguard. In 2025, there were no records of litigation or concluded cases involving corruption.

Whistleblowing Mechanism Enhancement

In strengthening internal supervision and compliance governance, Da Ren Tang has actively established a multi-dimensional and comprehensive mechanism for collecting and handling reports of issues. Dedicated email and reporting hotlines have been established to ensure the timely receipt of all types of reportable concerns.



To ensure thorough investigation and standardized handling of reported matters, we have formulated the "Unified Management Measures for Handling Problem Clues by the Discipline Inspection and Supervision Department of Tianjin Pharmaceutical Da Ren Tang" and the "Implementation Measures for Handling Discipline Inspection and Supervision Petitions and Reports of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.". We handle reported matters through interviews, written inquiries, and the retrieval of relevant documentation. To protect whistleblowers, information regarding reported issues, the reporting individual, and the reported party is kept confidential in accordance with the principle of safeguarding the democratic rights of petitioners. Upon completion of the verification process, investigation results of anonymous reports are reported to the Company's Party Committee or the Discipline Inspection Commission of Tianjin Pharmaceutical Group, while results of named reports are communicated to the whistleblower.

Integrity Safeguard Reinforcement

During the Reporting Period, we organized 12 affiliated enterprises to carry out special inspections focusing on issues such as "centralized rectification of improper hospitality" and "discipline inspection personnel's improper alcohol consumption", and conducted a comprehensive review of outsourced services in key operational areas. Based on identified issues, six corrective recommendations were proposed. In addition, we conducted anti-corruption and integrity education through warning education activities, corporate WeChat communications, and branch study sessions, covering 3,890 employees, with an average training duration of 8 hours per person. Through vivid case studies and diverse educational formats, we continuously strengthened employees' awareness of integrity and discipline. For key positions such as marketing and procurement, 1,934 employees signed the "Integrity Commitment Letter", establishing integrity safeguards at the source, with a 100% signing rate. At the same time, we widely carried out short video collection activities such as "A Word on Integrity" and "Reading Integrity Books", encouraging employee participation in integrity initiatives. Ten employees were recognized with awards for outstanding work, fostering a strong culture of integrity within the Company.

we organized **12** affiliated enterprises to carry out special inspections focusing on issues such as "centralized rectification of improper hospitality" and "discipline inspection personnel's improper alcohol consumption"

we conducted anti-corruption and integrity education, covering **3,890** employees,

with an average training duration of **8** hours per person.

1,934 employees signed the "Integrity Commitment Letter"

with a **100**% signing rate

we carried out short video collection activities such as "A Word on Integrity" and "Reading Integrity Books"

10 employees were recognized with awards



Indicator	Unit	2025	Participation
Number of Directors Receiving Anti-Corruption Training	Persons	3	33%
Number of Senior executives Receiving Anti-Corruption Training	Persons	4	100%
Number of Employees Receiving Anti-Corruption Training	Persons	3,890	100%

Anti-Monopoly and Fair Competition

Management System Enhancement

Da Ren Tang adheres to the principle of fair competition, safeguards the lawful rights and interests of consumers and the public interest in accordance with the law, and opposes fraudulent, coercive, collusive, obstructive, and other illegal or non-compliant practices. The Company strictly prohibits monopolistic and unfair competition practices that may infringe upon the legitimate rights and interests of other market participants or consumers or disrupt the market competition order.

The Company conducts market operations in compliance with applicable laws and regulations and has formulated and implemented the "Anti-Monopoly Compliance Guidelines of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", clarifying the objectives, principles, and scope of application of anti-monopoly compliance management, preventing monopolistic conduct and unfair competition risks, and effectively safeguarding fair market order and the legitimate rights and interests of partners and consumers.



In terms of governance structure, the General Manager's Office Meeting oversees major matters relating to anti-monopoly compliance management. The Legal and Compliance Department, as the lead department, is responsible for the formulation and updating of anti-monopoly policies, compliance risk identification and assessment, compliance review, supervision and inspection, and training and communication. Business and functional departments embed anti-monopoly compliance requirements into business processes and job responsibilities, forming a coordinated management mechanism with clearly defined responsibilities.

In 2025, the Group recorded no litigation cases or major administrative penalties arising from unfair competition.

Risk Control Enhancement

The Company has established a full-process risk control mechanism encompassing pre-event assessment, in-process inspection, and post-event rectification. Employees are provided with anti-monopoly compliance consultation and training support to continuously enhance compliance awareness and risk identification capabilities. We conduct anti-monopoly compliance reviews of significant matters involving market competition, covering commercial contracts, investment and merger agreements, and various marketing materials. Particular attention is given to preventing horizontal and vertical monopoly agreements, abuse of market dominance, and illegal implementation of business concentration. At the same time, the Company has clarified management requirements for competitively sensitive information to prevent improper disclosure during business operations and external communications.

Responsible Marketing

Governance

Da Ren Tang attaches great importance to responsible marketing and strictly complies with applicable laws and regulations in its operating jurisdictions, including but not limited to the *Consumer Protection Law of the People's Republic of China* and the *Advertising Standards Authority of Singapore (ASAS)*. The Company has established and continuously improved its institutional framework, formulating policies such as the "Market Access Compliance Guidelines", "Drug Trading Compliance Guidelines", "Pharmacy Promotion Compliance Guidelines", and "Drug Online Sales Compliance Guidelines" to guide marketing activities. In addition, the Company has established an internal review mechanism to conduct routine reviews of advertising content, product packaging, and promotional materials to ensure that information is truthful, accurate, and transparent, thereby preventing risks of false or exaggerated promotion.

Strategy

Da Ren Tang integrates fair competition and cultural respect into its responsible marketing strategy, enhancing brand credibility and strengthening inclusiveness across diverse global markets. We firmly oppose false advertising, exaggerated claims, and misleading statements, and are committed to ensuring that marketing content is truthful, accurate, and transparent, thereby safeguarding consumers' right to information and lawful rights and interests. We respect regional cultural differences and ensure that marketing materials and advertising language are available in Chinese, English, Malay, and Tamil, enabling consumers from diverse cultural backgrounds to access product information equally and accurately.

Risk and Opportunity Management

The Company regards marketing compliance as an integral component of its compliance management system and continuously promotes the upgrading of policies and processes to adapt to increasingly stringent pharmaceutical industry regulation and evolving market conditions. In 2025, focusing on third-party management and the standardization of promotional activities, the Company unified access standards for promotional service providers and standardized marketing contract templates, while strengthening on-site verification and dynamic management of third-party promotional service providers.

At the same time, we actively advanced the digitalization of promotional evidence management, strengthening process digitalization and standardization. By embedding compliance requirements into business processes and coordinating institutional, procedural, and technological measures, we proactively identify and prevent marketing risks and continuously enhance the systematic nature and execution capability of marketing compliance management.

In addition, we regularly provide employees with training on marketing, advertising, and sales compliance to ensure that they remain informed of the latest regulatory developments and market trends.

Case Comprehensive Compliance Training for Marketing Personnel

On 6 May 2025, Da Ren Tang organized a thematic compliance training session for all marketing personnel within the Health Technology segment. Under the theme "The New Normal of Pharmaceutical Compliance – System Upgrading and Scenario-Based Implementation Strategies under the Regulatory Environment", the training systematically interpreted core marketing compliance requirements and typical risk scenarios in light of evolving regulatory conditions in the pharmaceutical industry. By integrating institutional requirements with practical business scenarios, the training further clarified compliance boundaries and operational standards in marketing activities and enhanced marketing personnel's compliance awareness and risk prevention capabilities.



Indicators and Targets

The Company strengthens compliance management effectiveness through institutional implementation and digital tools. In 2025, the Company completed 56 cumulative revisions of marketing compliance-related systems and guidelines. Marketing expense review, evidence chain management, and documentation storage achieved 100% digitalization. In 2025, the promotional evidence digitalization system completed internal testing and initiated regional pilot implementation, gradually realizing full-process traceability of promotional activities.



02 Following the Rhythm of Nature and Safeguarding Lucid Waters and Lush Mountains

Environmental Compliance Management	43
Green Operations Implementation	45
Addressing Climate Change	54
Ecological Resource Protection	56



Da Ren Tang consistently adheres to the principle of green development and fully recognizes the Company's reliance on natural resources and the ecological environment. Focusing on key areas including energy and resource management, pollution prevention and control, climate change response, and ecological protection, we continuously improve institutional systems and management mechanisms, integrate green requirements throughout the entire production and operational process, and promote the harmonious coexistence of corporate development and ecological protection.



Environmental Compliance Management

Governance

Da Ren Tang upholds the philosophy of green development and places environmental protection at the core of its operations, establishing a scientific and standardized environmental management system. We are committed to integrating sustainable development principles into every aspect of corporate operations. In environmental management practices, the Group strictly complies with a series of applicable laws and regulations, including the *Environmental Protection Law of the People's Republic of China* and the *Law of the People's Republic of China on the Prevention and Control of Atmospheric Pollution*. At the same time, we continuously strengthen internal institutional development and implementation by formulating systems such as the "Environmental Risk Investigation and Hidden Danger Rectification System" and the "Emergency Management System for Sudden Environmental Incidents", thereby enhancing the scientific rigor and standardization of environmental management and ensuring that all production activities comply with relevant legal requirements and standards.

In 2025, we further advanced the establishment and enhancement of the environmental management system. Four subsidiaries—Long Shun Rong Pharmaceutical Factory, No. 6 Chinese Medicine Plant, Le Ren Tang Pharmaceutical Factory, and Darentang Pharmaceutical Factory—have newly obtained ISO 14001:2015 Environmental Management System certification. As of the end of the reporting period, 6 subsidiaries of the Group have obtained and maintained valid ISO 14001 Environmental Management System certifications.

Strategy

The Company regards environmental compliance as a fundamental requirement for prudent operations and sustainable development. We proactively benchmark against national and local environmental laws and regulations, industry regulatory policies, and technical standards, and continuously refine internal management standards. At the strategic level, guided by the principle of "prevention first, combined with control and remediation", the Company integrates environmental compliance requirements into business decision-making and project management at an early stage. We promote a shift from ex post rectification to prior prevention and process control, thereby providing institutional safeguards for the long-term stable operation of our business.

Impact, Risk, and Opportunity Management

Environmental Risk Management

In terms of environmental risk management, the Group emphasizes the identification of environmental risks and the enhancement of emergency response capabilities. During the reporting period, we conducted 10 special environmental inspections, identifying 57 issues and potential risks. Effective corrective measures were implemented to ensure the effectiveness and continuous improvement of environmental management. In addition, to strengthen our capacity to respond to environmental emergencies, we organized 12 environmental emergency drills. By simulating real-life scenarios, we tested and reinforced the emergency response capabilities of various departments.

we conducted **10** special environmental inspections and effective corrective measures were implemented

organized **12** environmental emergency drills

Environmental Training and Education

We attach great importance to cultivating and enhancing employees' environmental awareness. During the reporting period, we successfully organized 20 environmental training sessions covering employees at multiple levels. Through training and awareness initiatives, we further promoted environmental protection principles across the organization.

we successfully organized **20** environmental training sessions



Carbon Emissions Management Capacity-Building Training Session



Cleaner Production Training



2025 Environmental Work Inspection

Indicators and Targets

During the reporting period, the Company continued to increase investment in environmental protection. The total environmental protection investment for the year amounted to RMB 3.9744 million, which was used for the operation and maintenance of pollution prevention facilities, environmental improvement projects, and routine environmental management activities. At the same time, the Company placed strong emphasis on strengthening environmental management capabilities. A total of 20 environmental training sessions were conducted, with 1,509 participant attendances and cumulative training hours of 9,858.5 hours. These efforts further enhanced employees' environmental compliance awareness and operational capabilities in pollution prevention and control, laying a solid foundation for the continuous improvement of environmental management standards and standardized operations.



Our annual targets and progress are as follows:

FY2025 Target	FY2025 Progress
Environmental Compliance	<ul style="list-style-type: none"> Zero major environmental pollution incidents; No environmental administrative penalties; Implementation of pollutant discharge permit applications and filing of emergency response plans, with regular environmental emergency drills conducted.
FY2026 Target	Planned Actions
Environmental Compliance	<ul style="list-style-type: none"> Improve the environmental target accountability system and sign annual environmental responsibility agreements with affiliated units; Strengthen environmental compliance self-inspections and special inspections, establish a closed-loop rectification mechanism for identified issues, and prevent environmental risks; Reinforce supervision, assessment, and training dissemination to enhance employees' compliance awareness and management capabilities.

Waste Disposal and Emission of Pollutants

Governance

Da Ren Tang attaches great importance to ecological and environmental protection and remains committed to maintaining the routine operation of "low emissions" of pollutants. We strictly comply with relevant national laws and regulations, including the *Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste*, the *Law of the People's Republic of China on the Prevention and Control of Atmospheric Pollution*, and the *Law of the People's Republic of China on the Prevention and Control of Water Pollution*. We have formulated and implemented a series of standardized management systems and technical measures, including the "Environmental Protection Management System", the "Hazardous Waste Environmental Management System", and the "Environmental Protection Facility Equipment Operation Regulations Management System", to strictly regulate compliance control mechanisms for wastewater, waste gas, and solid waste emissions, thereby laying a solid foundation for achieving environmental protection objectives.

Meanwhile, we have established an organizational structure characterized by unified Group leadership, professional coordination by the EHS Department, graded accountability of subsidiaries, and clearly assigned individual responsibilities. Through institutionalized management, position-based accountability, and regular supervision and inspections, we ensure that three-waste control requirements are effectively implemented across all stages of production and operations.

Strategy

In line with the environmental management policy of "prevention first, combined with control and remediation", the Company integrates three-waste control into its annual business plans, continuously advances cleaner production and process optimization, and strengthens the construction and operational management of pollution prevention and control facilities. For new, modified, and expanded projects, we strictly implement the "three simultaneities" requirement for environmental protection facilities, reducing pollutant generation and emissions at the source.

Impact, Risk, and Opportunity Management

In wastewater discharge management, we implement the requirements of the "Water Ten Measures", ensuring that the discharge concentrations of characteristic pollutants such as COD, ammonia nitrogen, pH value, and heavy metals remain below regulatory limits and that total pollutant emissions comply with overall control requirements. The wastewater generated mainly consists of industrial wastewater and domestic sewage, both of which are treated through enterprise- or park-level wastewater treatment systems before being discharged into downstream municipal wastewater treatment plants via the municipal pipeline network. Our wastewater treatment systems are equipped with multiple mature and effective treatment technologies to ensure stable and efficient operation. In 2025, the wastewater treatment station at the No. 6 Chinese Medicine Plant was officially put into operation. By introducing a "multi-phase electrocatalytic reactor" combined with UASB anaerobic processes and biological aerobic treatment technologies, the factory transitioned from outsourced utilization to in-house harmless disposal of wastewater. During the reporting period, all industrial wastewater treatment facilities operated effectively, and all wastewater was discharged in compliance with applicable standards.

In waste gas management, we implemented the requirements of the "Air Ten Measures" and installed advanced treatment facilities to ensure compliant emissions. To strengthen the control of volatile organic compounds (VOCs), we adopted differentiated treatment devices—such as water spraying and activated carbon adsorption—based on production processes and main emission components, and ensured efficient operation through regular maintenance and replacement of consumables. We strictly implement the "one enterprise, one policy" emergency response management mechanism for heavy pollution weather. During the reporting period, Jing Wan Hong Pharmaceutical, Le Ren Tang Pharmaceutical Factory, No. 6 Chinese Medicine Plant, and Darentang Pharmaceutical Factory upgraded their VOC treatment facilities, replacing original photocatalytic oxidation processes with activated carbon adsorption processes, thereby further enhancing treatment efficiency and operational stability. All treated waste gas was discharged in compliance with relevant standards.



VOC Environmental Equipment Upgrade

In waste management, we consistently adhere to green environmental principles and adopt differentiated treatment methods according to waste classification to ensure safe and compliant disposal. General industrial solid waste generated by subsidiaries is handled through classified collection, entrusted disposal, and recycling. Domestic waste is collected and transported by local sanitation departments. For hazardous waste generated during production and operations—such as activated carbon and waste reagent bottles—we have established "Dangerous Waste Management System" and strictly implement unified collection and storage procedures, standardized labeling of hazardous waste storage areas, ledger management, regular filing in the hazardous waste supervision information system, and entrusted disposal by qualified third-party entities.

We continuously improve the operation and maintenance mechanisms of pollution prevention and control facilities and steadily enhance environmental governance capacity. In 2025, the monitoring frequency of pollutant discharge outlets and the effective transmission days of online monitoring systems at all production units complied with government regulatory requirements. Through systematic management and technical safeguards, Jing Wan Hong Pharmaceutical was recognized as a National-Level "Green Factory", and the No. 6 Chinese Medicine Plant was recognized as a Tianjin "Premium Zero-Waste Factory", reflecting phased achievements in green manufacturing and solid waste reduction management. As of the end of the reporting period, the Group's factories received the following green recognitions:



Entity Name	Certification	Level
Tianjin Da Ren Tang Jingwanhong Pharmaceutical Co., Ltd.	Green Factory	National Level
No. 6 Chinese Medicine Plant of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Green Factory	Tianjin City
Long Shun Rong Pharmaceutical Factory of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Green Factory	Tianjin City
Le Ren Tang Pharmaceutical Factory of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Green Factory	Tianjin City
Darentang Pharmaceutical Factory of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Green Factory	Tianjin City
No. 6 Chinese Medicine Plant of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Premium Zero-Waste Factory	Tianjin City
Medicinal Materials Company of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Zero-Waste Factory	Tianjin City
Le Ren Tang Pharmaceutical Factory of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.	Zero-Waste Factory	Tianjin City
Tianjin Da Ren Tang Jingwanhong Pharmaceutical Co., Ltd.	Zero-Waste Factory	Tianjin City

Indicators and Targets

The Company takes compliant disposal and standard-compliant emissions of pollutants as annual targets and continuously advances waste reduction, resource utilization, and standardized management. We manage key indicators such as pollutant concentration levels, stable operation rates of treatment facilities, and compliant disposal rates of hazardous waste to ensure ongoing compliance with national and local emission standards, while progressively optimizing emission structures and treatment efficiency.

Our annual targets and progress are as follows:

FY2025 Target	FY2025 Progress
Compliant Disposal and Standard-Compliant Emissions	<ul style="list-style-type: none"> 100% compliance rate for wastewater and waste gas pollutant concentration and total emission levels; 100% effective operational rate of environmental protection facilities; 100% lawful disposal rate of hazardous and general solid waste.
FY2026 Target	Planned Actions
Compliant Disposal and Standard-Compliant Emissions	<ul style="list-style-type: none"> Continue online monitoring, entrusted monitoring, and self-monitoring; Strengthen classified and zoned storage of solid waste, with unified labeling, ledger management, and transfer documentation.

Status of the Company's Wastewater, Waste Gas and Solid Waste Discharge

Wastewater		Unit	2025
Wastewater Discharge Volume		Tons	148,644.50
Wastewater Discharge Intensity		Tons/m ²	0.72
COD Emissions		Tons	12.68
Suspended Solids Emissions		Tons	7.89
Total Phosphorus Emissions		Tons	0.26
Total Nitrogen Emissions		Tons	1.54
Ammonia Nitrogen Emissions		Tons	25.11
Waste Gas		Unit	2025
Nitrogen Oxides		Tons	0.73
Sulfur Oxides		Tons	0.05
Particulate Matter		Tons	0.74
Volatile Organic Compounds (VOC)		Tons	2.07
Solid Waste		Unit	2025
Hazardous Waste		Tons	461.79
Hazardous Waste Intensity		Tons/m ²	0.002
Non-Hazardous Solid Waste		Tons	3,385.34
Non-Hazardous Waste Intensity		Tons/m ²	0.02

Energy Management and Resource Management

Governance

To effectively promote efficient energy utilization and management, the Group has established a comprehensive energy management system and formulated the "Energy Management Regulations" and "Energy Management Manual", which clearly define the energy management policy, responsibilities, and energy usage requirements. We stipulate that the responsible executive manager oversees energy management across the Company system, with the Supply Chain Management Center serving as the dedicated energy management department. Full-time energy management personnel are appointed to carry out specific responsibilities, forming a three-tier energy management system at the corporate level. In addition, industrial subsidiaries are required to establish a three-level energy management framework at the plant, department, and team levels.

We have continued to advance the development of our energy management system. As of the end of the reporting period, four subsidiaries had obtained valid ISO 50001 Energy Management System certifications.



Strategy

The Company focuses on improving resource utilization efficiency, reducing energy consumption per unit of output, and lowering greenhouse gas emissions. Energy conservation and consumption reduction serve as key drivers for advancing green manufacturing and high-quality development. At the beginning of 2025, based on recommendations from external energy audits, the Company clarified annual energy management targets, established an energy-saving project list and energy-saving control indicators, and allocated targets to subsidiaries, forming a mechanism characterized by clear objectives, defined responsibilities, and controllable processes.

Impact, Risk, and Opportunity Management

Da Ren Tang promotes refined energy management and energy-saving practices through improved governance mechanisms, optimization of the energy structure, and technological transformation.

Strengthening Energy Audits

The Company continuously enhances its energy governance capacity. In May 2025, it successfully passed the annual external energy audit organized by the Tianjin Development and Reform Commission. Based on audit feedback, ongoing optimization of energy efficiency levels was conducted at each plant, providing data support for energy-saving improvements.

Optimizing the Energy Structure

The Company actively promotes the application of clean and renewable energy through solar lighting systems, participation in green electricity market transactions, and optimization of energy usage schedules and structures.

Key Initiatives in 2025

Outdoor lighting at the Da Ren Tang Modern Traditional Chinese Medicine Industrial Park was fully powered by solar energy, achieving 100% renewable energy usage.

Approximately 35% of streetlights and ground lights at Le Ren Tang Pharmaceutical Factory, No. 6 Chinese Medicine Plant, Jingwanhong Pharmaceutical, and Xinxin Pharmaceutical Plant were converted to solar power.

The rooftop photovoltaic and small wind power project at Da Ren Tang Building generated approximately 43,400 kWh annually, enabling self-consumption with surplus electricity fed into the grid.



Solar Streetlight Upgrade Project

Promoting Energy-Saving Technological Transformation

The Company focused on three core areas: optimization of energy-using equipment, process technology optimization, and building energy efficiency improvement. During the reporting period, 12 key projects were completed, achieving comprehensive energy-saving breakthroughs.

During the reporting period,
12 key projects were completed

Key Initiatives in 2025

Energy-Using Equipment Optimization

Xinxin Pharmaceutical Plant, Long Shun Rong Pharmaceutical Factory, and Le Ren Tang Pharmaceutical Factory upgraded core production lines, replacing transformers, upgrading refrigeration units, and installing high-efficiency circulating pumps, achieving annual savings of 21.47 tons of standard coal.

Process Technology Optimization

Zhongxin Pharmaceutical Plant implemented a low-temperature vacuum dryer heating source electrification project, expected to save 27.93 tons of standard coal annually.
Long Shun Rong Pharmaceutical Factory implemented a chilled water system energy-saving project, reducing electricity and water losses and achieving annual savings of 12.31 tons of standard coal.

Building Energy Efficiency Optimization

Darentang Pharmaceutical Factory, Xinxin Pharmaceutical Plant, and Long Shun Rong Pharmaceutical Factory completed lighting upgrades, saving 5.82 tons of standard coal annually.
Long Shun Rong Pharmaceutical Factory and the Modern Traditional Chinese Medicine Industrial Park upgraded air conditioning and heating systems, achieving annual savings of 11.54 tons of standard coal.

Case Xinxin Pharmaceutical Plant High-Efficiency Transformer Upgrade Project

In 2025, Xinxin Pharmaceutical Plant replaced high-loss transformers with high-efficiency models, reducing operational losses by approximately 3% and achieving annual savings of 6.61 tons of standard coal while ensuring a stable power supply.

replaced high-loss transformers with high-efficiency models, reducing operational losses by approximately

3%

achieving annual savings of

6.61

tons of standard coal



Case Zhongxin Pharmaceutical Plant Dryer Heat Source Retrofit and Air Compressor Waste Heat Recovery Project

In early 2025, Zhongxin Pharmaceutical Plant completed upgrades to its drying system and waste heat recovery system, improving energy efficiency and achieving annual savings of 28 tons of standard coal.



achieving annual savings of

28

tons of standard coal

Cultivating Energy-Saving Awareness

Da Ren Tang integrates internal training and external learning to enhance employees' awareness and professional competence in energy conservation. In 2025, special training sessions were conducted covering audit summaries, energy-saving policies, and technologies. Energy Conservation Week activities included promotional posters, online quizzes, and energy-saving idea collections, with employee participation exceeding 50%.



In terms of external exchanges and learning, we actively build platforms for professional learning and industry benchmarking. We organized more than 50 person-times of professionals to participate in 4 industry exchange events, including the First Tianjin Pharmaceutical Green Intelligent Manufacturing Leaders Conference and the 2025 Public Building Energy Saving and Carbon Reduction Technology Exchange Roving Forum (Tianjin). Through thematic seminars, case sharing, and technical demonstrations, we gained an in-depth understanding of cutting-edge energy-saving technologies and management expertise in the pharmaceutical sector.



In terms of water resource management, we continuously strengthen refined water management practices and promote standardized, efficient, and circular water use processes. The Company has established a regular reporting mechanism requiring all industrial subsidiaries to submit "Tianjin Industrial Enterprises Energy and Water Consumption Regular Report" monthly as stipulated. During routine operations and maintenance, we reinforce equipment inspections to eliminate leakage, overflow, and wastage. During the reporting period, the Company prioritized the enhancement of water metering management and implemented tiered monitoring at the point of use, gradually achieving total water consumption control and graded management. These measures provide a solid management foundation for rational water utilization and consumption reduction.

The Group actively promotes multi-purpose water use and water recycling practices, strongly advocating for the reuse of production water and the recovery and reutilization of steam condensate, thereby effectively improving water resource utilization efficiency. In 2025, Le Ren Tang Pharmaceutical Factory and Long Shun Rong Pharmaceutical Factory completed purified water concentrate reuse retrofit projects, achieving annual water savings of approximately 2,500 tons.

The Company continues to cultivate water conservation awareness. During Water Conservation Promotion Week, we reinforced employees' water-saving concepts through the dissemination of water conservation videos and promotional materials on water-saving equipment.



achieving annual water savings of approximately

2,500 tons



Indicators and Targets

The Company has continuously strengthened water resource and energy management. In 2025, both the energy consumption and water consumption per unit output value of the Company decreased year-on-year.

The Company's energy and water consumption		
Energy Consumption	Unit	2025
Purchased Electricity Consumption	Ten thousand kWh	2,154.51
Natural Gas	Ten thousand m ³	162.91
Diesel	Tons	105.51
Gasoline	Tons	2.28
Purchased Heat	One million kJ	75,609.56
Total Energy Consumption	Tce	7,549.98
Water Consumption		
Unit	2025	
Total Water Consumption	Tons	231,200
Water Intensity	Tons/m ²	1.11
Recycled Water Volume	Tons	1,890,000
Water Saved	Tons	2,500

Our annual targets and progress are as follows:

Issue	FY2025 Target	FY2025 Progress
Energy Management	Reduce energy consumption by 50 tons of standard coal	<ul style="list-style-type: none"> Completed 12 energy-saving projects, achieving savings of 66.76 tons of standard coal. Successfully passed the energy metering review led by Tianjin Institute of Metrology experts.
	FY2026 Target	Planned Actions
	Reduce energy consumption by 50 tons of standard coal	<ul style="list-style-type: none"> Strengthen internal audits and metering management, and integrate AI and digital tools in training. Track policy developments and improve management systems. Introduce new technologies and equipment to achieve savings targets.

Addressing Climate Change

Issue	FY2025 Target	FY2025 Progress
Water Resource Management	Improve rational water use	<ul style="list-style-type: none"> Expanded purified water concentrate reuse from Darentang Pharmaceutical Factory to Le Ren Tang Pharmaceutical Factory and Long Shun Rong Pharmaceutical Factory, saving approximately 2,500 tons annually.
	FY2026 Target	Planned Actions
	Promote steam condensate and purified water reuse	<ul style="list-style-type: none"> Systematically expand reuse projects to reduce freshwater withdrawal and discharge.

Circular Economy

Raw Material Management

The Group's Supply Chain Management Center is responsible for the centralized coordination of the procurement, inspection, storage, and utilization of raw materials, auxiliary materials, and packaging materials. In packaging management, we continuously advance lean and standardized control, taking quality stability and resource utilization efficiency as core objectives. Through source management and process control, we reduce material losses. In procurement and supply chain management, the Company strengthens collaborative management with core suppliers, conducting targeted improvements for key raw materials and packaging materials, and advancing process standards and quality requirements to earlier stages of the supply chain.

In 2025, the Company optimized packaging design for key products. To address quality stability challenges associated with the traditional hot-branded packaging of Qinggong Shoutao Wan, we established a strategic collaboration mechanism with core packaging suppliers and conducted targeted technical improvements. By defining key process parameters and quality assessment standards for raw materials and manufacturing processes, and establishing a full-process inspection mechanism covering "raw material receipt – production process – finished product release", we effectively reduced packaging defect rates and raw material losses, improved material utilization rates, and enhanced yield performance. These measures ensured stable and controllable packaging quality while minimizing material waste and achieving refined procurement management.

In the management of key raw materials such as traditional Chinese medicinal materials, the Company pays close attention to their ecological origins and sustainability. Relevant measures on cultivation, traceability, and biodiversity protection are detailed in the section "[Ecological Resource Protection](#)".

Resource Recycling and Reuse

The Company actively promotes circular economy practices and continuously improves resource utilization efficiency. Regarding medicinal residue disposal, we cooperate with professional third-party partners. On the one hand, medicinal residues are processed through dehydration and crushing to produce biomass fuel briquettes, enabling energy recovery and resource recycling, and providing new solutions for green production. On the other hand, traditional Chinese medicinal residues are treated through aerobic fermentation and utilized as nutrient substrates or organic fertilizers for landscaping and reed seedling cultivation, thereby achieving reduction, stabilization, harmless treatment, and resource utilization of medicinal residues.

At the same time, we practice green office principles and actively promote paperless operations. Through the adoption of electronic workflows and double-sided printing, we significantly reduced paper consumption. In 2025, the total volume of recycled and reused waste within the Group reached 3,254.66 tons.

Addressing Climate Change

Climate change has become one of the most pressing global challenges of our time. We actively respond to climate change and strengthen internal management in this regard. In 2025, we identified climate-related risks and opportunities. Our disclosure on climate change response is still at an early stage, and we will gradually deepen our disclosures on the "Addressing Climate Change" topic in the future.

Governance

The Group has established a comprehensive climate governance structure to ensure that climate-related risks and opportunities are effectively identified, managed, and addressed.

The Board of Directors, as the highest decision-making body, is responsible for overseeing climate-related risks and opportunities. Under the Board, the Strategic and Sustainable Development Committee has been established to regularly review climate-related matters and annually examine sustainability reports that include topics such as "Addressing Climate Change". The Company has also established a Sustainability Working Group as the operational liaison body for the Strategic and Sustainable Development Committee. The working group is responsible for overseeing the setting of targets, implementation of strategies, and progress toward achieving goals related to climate-related and other sustainability-related impacts, risks, and opportunities.

Strategy

The Group has identified potential climate-related risks and opportunities it may face and has conducted a comprehensive assessment of their potential financial impacts.

Risk Type	Specific Risk	Risk Description	Potential Financial Impact
Physical Risk	Extreme weather events such as floods and typhoons	Extreme weather may damage production facilities and disrupt logistics and transportation. As the Company's upstream supply relies on medicinal herb cultivation, extreme weather may also affect herb yields and the supply of raw materials.	Potential equipment losses, reduced production efficiency, business interruptions, and increased logistics costs lead to higher operating expenses.
	Sea level rise	Rising sea levels may damage fixed assets and disrupt the supply chain.	Damage to production facilities and warehouses may require significant capital for reconstruction, repair, and reinforcement, increasing capital expenditures. Supply chain disruptions may also increase supply chain costs.
Transition Risk	Policy and regulatory risk	Governments may introduce stricter carbon emission or environmental regulations.	The Company may need to increase the proportion of clean energy used and invest in environmental protection facilities, resulting in additional financial expenditures.
	Market risk	Growing market demand for low-carbon products may reduce the market share of traditional products.	Declining market share may reduce revenue.
	Technology risk	New environmental technologies may need to be adopted to avoid technological obsolescence.	Increased R&D investment and the replacement of outdated equipment may raise operating costs.
Reputational risk	Stakeholders may impose higher expectations for sustainability disclosure.	Damage to the Company's reputation may reduce brand value and negatively affect business operations and revenue.	



Ecological Resource Protection

Resource Protection Philosophy

As a traditional Chinese medicine manufacturer, Da Ren Tang relies heavily on natural ecosystems for its raw materials, with approximately 95% of the Chinese medicinal materials used derived from plant and animal natural resources.

The Group fully recognizes the close relationship between the sustainability of Chinese medicinal material resources and biodiversity conservation. It regards "ecological protection, rational utilization, and sustainable development" as key principles for the management of Chinese medicinal materials. Biodiversity protection is integrated into the full lifecycle of Chinese medicinal materials, including procurement, cultivation, research and development, and storage. Through scientific resource management and technological innovation, the Company is committed to building a traditional Chinese medicine industry ecosystem in which humans and nature coexist harmoniously.

Standardized Source Management

For Chinese medicinal material raw materials, the Company adopts a model combining external procurement and cooperative cultivation, and has established standardized cooperative cultivation bases for key medicinal materials. As of the end of 2025, Da Ren Tang has established planting bases covering 45 varieties of Chinese medicinal materials, with a total area of approximately 26,000 mu. The Company continues to advance the construction of a full-variety traceability system, appoints dedicated personnel to manage the traceability system, and supervises suppliers in standardizing the reporting of planting, harvesting, and circulation information, thereby improving the transparency and traceability of the sources of Chinese medicinal materials.



The planting bases with a total area of approximately

26,000 mu

As of the end of 2025, planting bases has established covering

45 varieties of Chinese medicinal materials

Opportunity Type	Opportunity Description	Potential Financial Impact
Resource efficiency	Optimize production processes to improve resource utilization efficiency.	More efficient use of resources can reduce production costs.
Energy sources	Adoption of renewable energy and innovation in low-carbon pharmaceutical technologies.	Reduced energy costs and improved long-term profitability; lower production costs and enhanced market competitiveness.
Products and services	Demand for health products may increase under extreme climate conditions, driving higher product sales.	Increased product sales may boost revenue.
Markets	Growing recognition of traditional Chinese medicine in more countries creates opportunities for international market expansion.	Expanded markets may lead to increased revenue.
Resilience	Implementation of energy-saving measures.	Enhanced climate resilience helps support stable business operations.


Impact, Risk and Opportunity Management

In 2025, we further reviewed climate-related risks based on its operational context. The identified climate risks were analyzed from two key dimensions: physical risks and transition risks. For physical risks, the Company carefully assessed the potential threats posed by extreme weather events to production facilities, warehousing and logistics systems, and upstream raw material supply bases. For transition risks, the Company analyzed the potential impacts of policy and regulatory changes, green technology innovation, and shifts in market demand on its operating model. In the future, we will continue to dynamically identify and assess climate-related risks.

In terms of physical risk management, the Group continuously monitors extreme weather events and long-term climate trends, and adjusts production operations and infrastructure accordingly. The Company has developed climate disaster response plans, established a disaster prevention and mitigation leadership group, appointed dedicated personnel to issue timely climate disaster warnings, and conducted routine inspections and drills to reduce the potential impacts of climate change. In addition, the Company is promoting upstream industry integration and improving supply chain resilience through measures such as strategic inventory reserves when appropriate. In terms of transition risk management, Da Ren Tang actively responds to the impacts of factors such as policy and regulatory developments and evolving market conditions on its business. The Company seeks to prevent the potential financial impacts of transition risks by adopting measures such as optimizing production processes.

Indicators and Targets

China has proposed striving to reach peak carbon dioxide emissions before 2030 and making efforts to achieve carbon neutrality before 2060. Da Ren Tang continuously monitors its greenhouse gas emissions and works toward this goal within its own operational scope. During the reporting period, Da Ren Tang took key products as the entry point and actively promoted product-level carbon emission management practices. The Company selected 3 key products (Jingwanhong Ointment, Biqi Capsules, and Tongmai Yangxin Wan) to conduct product carbon footprint accounting and obtained third-party product carbon footprint verification statements, providing a data basis for the Company to further identify product emission reduction potential and optimize processes and supply chain management.



In 2025, we calculated its greenhouse gas emissions. The greenhouse gas emission data for the reporting period are as follows:

Emission Type	Unit	2025
Scope 1 Greenhouse Gas Emissions	tCO ₂ e	3,870.12
Scope 2 Greenhouse Gas Emissions	tCO ₂ e	22,021.89
Total Greenhouse Gas Emissions (Scope 1 + Scope 2)	tCO ₂ e	25,892.01
Greenhouse Gas Emission Intensity (Scope 1 + Scope 2)	tCO ₂ e/m ²	0.12



Da Ren Tang Pinellia Planting Base



Da Ren Tang Schisandra Planting Base



Da Ren Tang Ligusticum chuanxiong Planting Base

Certification status of Da Ren Tang cooperative cultivation bases:

2 planting bases for Ligusticum chuanxiong and Lonicera japonica have passed the GAP compliance extension inspection conducted by the Tianjin Municipal Medical Products Administration.

6 varieties—Ligusticum chuanxiong, Schisandra, Lonicera japonica, Coptis chinensis, Magnolia officinalis, and Pinellia—have obtained the "three none and one all" certificate issued by the National Chinese Medicinal Materials Standardization and Quality Evaluation Innovation Alliance.

2

planting bases have passed the GAP compliance extension inspection conducted by the Tianjin Municipal Medical Products

6

varieties have obtained the "three none and one all"

Environmentally Friendly Cultivation

Through standardized management and integrated prevention and control technologies, Da Ren Tang minimizes the impact of cultivation activities on natural ecosystems.

Method	Specific Measures
Standardized institutional management	Specific management systems are formulated for different Chinese medicinal material bases, strictly regulating production technical specifications and operating procedures for Chinese medicinal materials, including management systems for the use of agricultural inputs (fertilizers and pesticides) and pest and disease control measures.
Regulated chemical use	The use of highly toxic fumigants, sulfur fumigation, toxic anti-mildew agents, highly toxic pesticides, and growth regulators/herbicides is strictly prohibited. Soil and irrigation water are tested regularly to ensure that the ecological environment continuously complies with national standards.
Maintaining ecological balance	Integrated prevention and control methods are actively adopted, including the use of natural enemies and improvement of crop environments, to reduce interference with ecosystems and maintain the balance of agricultural ecosystems. Ecological and green cultivation models are promoted, with strengthened fertilizer management and water management throughout the cultivation process to further improve the quality of medicinal materials.
Environment-friendly maintenance	In the storage stage of Chinese medicinal materials, the Company continues to promote the upgrading of automated temperature and humidity control systems in warehouses, and three standard warehouses have been upgraded in 2025. Preservation technologies for Chinese medicinal materials are continuously improved, shifting from traditional sun-drying and stacking methods to modern preservation methods such as low-oxygen controlled atmosphere storage, effectively improving the quality of stored medicinal materials and reducing material loss and environmental impact.

Protection of Endangered Resources

For certain endangered animal-derived Chinese medicinal materials, Da Ren Tang strictly complies with national laws, regulations, and policy requirements and conducts raw material management in accordance with the law. The Company closely follows national policy adjustments and actively cooperates with universities and research institutions to promote research on substitute medicinal materials and related technologies. Through scientific research and innovation, the Company explores ways to reduce reliance on endangered species resources and promotes the sustainable utilization of Chinese medicinal material resources.

03

Inheriting Ancient Craftsmanship and Cultivating Talents of Shared Aspiration

Standardized Employment Management	61
Employee Training and Development	63
Employee Rights and Compensation	69
Employee Safety Assurance	73



Employee Employment and Diversification

Employee Training and Development

Employee Rights and Compensation

Occupational Health and Safety

Da Ren Tang advocates respect for diversity and equal opportunities, and is committed to building a standardized and orderly employment and organizational environment. The Company also regards employees' physical and mental well-being and work support as important aspects of its daily management. At the same time, through talent development and capability enhancement initiatives, the Company provides employees with learning and development pathways, promoting a positive interaction between individual growth and organizational development and supporting the Company's long-term stable operations.



Compliant Employment System

Da Ren Tang adheres to the principle of "people-oriented" management and regards compliant employment as an important foundation for human resources management and corporate sustainable development. The Company strictly complies with relevant laws and regulations, including the *Labor Law of the People's Republic of China*, the *Labor Contract Law of the People's Republic of China*, and the *Law of the People's Republic of China on the Protection of Laborers' Rights and Interests*. Through a standardized human resources management system, the Company protects the legitimate rights and interests of employees and promotes the coordinated advancement of employees' personal development and the Company's long-term growth.

The Company has established management systems covering employee recruitment, compensation management, training and development, and codes of conduct. During the reporting period, in accordance with current regulations and management needs, the Company formulated and issued the "Employee Mobility Management System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", the "Re-employment Management System for Retired Employees of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", the "Employee Growth Center Management System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", and the "Intern Management System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.". The Company also revised the "Labor Contract Management System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", and the "Recruitment Management System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", further clarifying requirements related to employee recruitment, contract signing, position adjustment, and other management matters to safeguard employees' legitimate rights and interests. In 2025, the Company had no violations related to employment that had a significant impact on its operations.







Equal Employment

Da Ren Tang is committed to fostering a fair, respectful, and diverse employment environment. Equal employment and human rights protection are incorporated into the Company's human resources management practices. Through a combination of institutional policies and daily management, the Company continuously safeguards employees' legitimate rights and interests and promotes the establishment of harmonious and stable labor relations.

During recruitment, hiring, and employee management, the Company strictly follows relevant laws, regulations, and labor standards, and adheres to the principle of equal employment. Job applicants and employees are not treated differently based on gender, age, ethnicity, religion, or educational background, ensuring that all candidates and employees can participate in competition and development in a fair environment. At the same time, the Company explicitly prohibits any form of discrimination, child labor, forced labor, or compulsory labor. Through management systems and organizational culture, the Company safeguards employees' dignity and prevents inappropriate behavior.

During the reporting period, the Company had no incidents related to discrimination, child labor, forced or compulsory labor, or human rights violations.

 Number of employees: 3,890



Talent Recruitment and Retention

In terms of talent recruitment and allocation, the Company continues to expand standardized and diversified recruitment channels, attracting outstanding talents from society and universities through campus recruitment, talent markets, online recruitment platforms, headhunting services, and employee referrals. The Company adheres to the principle of aligning job requirements with employees' capabilities. Professional background, personal qualities, and assessment results are comprehensively considered, with a focus on selecting talents with professional competence and development potential, thereby promoting a scientific and reasonable human resources allocation structure. At the same time, in accordance with the Employee Mobility Management System, the Company standardizes the management of internal mobility, position adjustments, and resignation procedures, guiding the orderly flow of talent. The Company pays attention to balancing employee stability with reasonable mobility, and reduces abnormal turnover risks by optimizing job matching and improving development support mechanisms, thereby enhancing the efficiency of talent allocation.

In 2025, the total number of employees of Da Ren Tang was 3,890, including 331 newly hired employees. Meanwhile, the internal employee mobility rate was 7.8%.

Number of employees at Da Ren Tang

3,890

Number of new employees hired

331

Internal employee mobility rate

7.8%

Total number of employees leaving

167

Employee turnover rate

4.3%


Employee Training and Development

Governance

Da Ren Tang regards employee development as an important support for high-quality corporate development and has established a relatively systematic governance framework for talent development based on corporate strategy and business development needs. The Company continuously improves institutional documents such as the "Employee Training Management System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd." and the "Internal Trainers Management System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", standardizing the formulation of training plans, implementation and organization, evaluation and assessment, and resource support. A scientific training evaluation mechanism has been established to track and provide feedback on training outcomes, better respond to employees' diverse learning needs, and enhance the systematic nature and effectiveness of training management.

Strategy

The Company adheres to a strategy-oriented and business-driven approach and builds an employee development system covering different job sequences and career stages through both online and offline learning channels, continuously enhancing overall organizational capabilities. In 2025, relying on the Da Ren Tang Sub-center of Jinyao Business Academy, the Company established a comprehensive professional capability development framework covering key areas including marketing, production, research and development, quality management, and functional departments. Through new employee development programs, talent pipeline cultivation, and professional capability improvement initiatives, the Company supports continuous employee growth and strengthens the talent foundation for long-term corporate development.



Impact, Risk and Opportunity Management

Focusing on employee development and organizational sustainability needs, the Company continuously improves promotion mechanisms, training systems, and supporting measures. Through systematic talent development arrangements, the Company reduces risks related to insufficient capabilities in key positions and talent loss, while capturing opportunities for improved organizational effectiveness brought by employee growth.

Employee Promotion Pathways

The Company provides employees with clear and transparent career development pathways and has established a dual-track system of "management and professional" career progression. Employees are supported in choosing development paths based on their strengths and career aspirations. By clarifying job requirements and competency standards, the Company guides employees to deepen their expertise in either management capabilities or professional technical fields, enhancing employees' development expectations and organizational stability.

Employee Training System

The Company adopts an integrated online and offline training model to promote the systematic enhancement of employee capabilities. Relying on the "Jinyao Cloud Learning Platform", the Company has established a self-directed learning mechanism. At the same time, centralized training sessions, thematic training camps, and practice-based projects are implemented to strengthen new employee onboarding, professional capability enhancement, leadership development, and compliance awareness. In addition, the Company encourages employees to continuously improve their professional capabilities and obtain relevant professional qualifications. The "Employee Training Management System of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd." specifies that expenses for training, examinations, and continuing education related to professional qualifications relevant to employees' positions are eligible for reimbursement, further enhancing the sustainability of employees' learning investment.

Key Training Cases

In 2025, the Company organized and implemented multiple training programs focusing on new employee development, professional capability enhancement, leadership development, and material issues, covering different job levels and business areas.

Case

Campus Recruitment New Employee Onboarding Training

In July 2025, Da Ren Tang organized onboarding training for newly recruited graduates, focusing on corporate culture understanding, product knowledge learning, and professional capability development to help new employees accelerate role transition and integration. The training lasted **three** days and was attended by **83** newly recruited graduates.



The training lasted **3** days

and was attended by **83** newly recruited graduates



Case Professional Skills Training

In July 2025, Da Ren Tang organized the "Retail TTT + Knowledge Enhancement Training Camp" for city managers and trainers from different regions across the country to enhance practical terminal business capabilities through centralized training. The training lasted **four** days and involved more than **70** participants.



In 2025, Da Ren Tang organized a series of training sessions titled "Learn Traditional Chinese Medicine and Use Chinese Medicine Well", focusing on topics such as the compatibility principles of Chinese patent medicines, clinical thinking in traditional Chinese medicine, and the integration of theory and practice. The program systematically enhanced employees' professional knowledge and application capabilities. **Three** sessions were held, with more than **350** participants in total.



In 2025, Da Ren Tang organized a training series on "Enhancement and Value Exploration of Chinese Patent Medicine Varieties", targeting personnel from medicinal materials, decoction pieces, technology, and quality management positions across multiple job levels to improve professional capabilities across the entire value chain of Chinese patent medicines. **Three** sessions were conducted with more than **260** participants.




Case New Media and AI Empowerment Training

During the reporting period, Da Ren Tang organized a "New Media and AI Empowerment Training" program for middle management personnel and key staff in marketing and market-related roles to promote the application of digital tools in business scenarios. The training lasted half a day and involved more than **60** participants.

During the reporting period, the Company also organized the "First AI Poster Creation Competition" for all employees, encouraging the application of artificial intelligence tools in brand communication and business scenarios through a competition format. A total of **44** works were submitted, of which **21** won awards, with an average exposure of **469** views per work and a total reach of more than **23,000** person-times.



In 2025, Da Ren Tang organized a series of training and practical activities under the "Xiaohongshu Co-creation Program", open to all employees. Through phased co-creation activities, the program enhanced employees' understanding and application of content creation and product communication on new media platforms. **Four** sessions were conducted, collecting a total of **534** works.



4
sessions were conducted

A total of
534 works were collected

Case Leadership Training

In 2025, Da Ren Tang collaborated with university resources to organize the "Advanced Program for Leadership Competence and Skills Enhancement", targeting leadership team members and talent pipeline candidates at different levels to systematically improve strategic thinking and management capabilities. Four sessions were held with more than 540 participants in total.



Employee training in 2025



Total employee training attendance
38,091 person-times



Average training hours per employee
66 hours

Our annual targets and progress are as follows:

FY2025 Target	FY2025 Progress
Promote employee development	<ul style="list-style-type: none"> Optimize the competency qualification system and establish competency standards for key functions; deepen employee development mechanisms, upgrade the training system, strengthen the internal trainer team, and expand the functions of the online learning platform; Improve succession planning, expand coverage of key positions, establish a dynamic evaluation mechanism, strengthen cross-departmental rotation, and introduce external expert guidance to enhance employee development; Establish diversified incentive mechanisms, foster a learning-oriented organizational culture, and improve employees' skills and innovation capabilities.

FY2026 Target	Planned Actions
Promote employee development	<ul style="list-style-type: none"> Improve strategy-based talent recruitment and development, deepen succession planning for key positions, and ensure a continuous supply of talent pipelines; Build a training system closely aligned with business needs, focusing on improving employees' professional skills and innovation capabilities to directly support business challenges and value creation; Continue expanding digital human resources applications and leverage the EHR system to achieve precise talent assessment and dynamic monitoring of talent development.

Indicators and Targets

Focusing on the long-term objective of promoting employee development, the Company continues to improve the indicator system for talent cultivation and development and advances the implementation of related targets in stages. In 2025, the Da Ren Tang online learning platform covered 3,890 users, with a cumulative learning duration of more than 100,000 hours. The average annual learning time per employee reached 2,049.52 minutes (31.16 hours). A total of 747 learning projects were released, and 568 courses were made available online, with continuous improvement in employee participation and platform content supply capacity.

the Da Ren Tang online learning platform covered
3,890 users

The cumulative learning duration of more than
100,000 hours

The average annual learning time per employee reached
2,049.52 minutes

A total of
747 learning projects were released

568 courses were made available online

As of the end of the reporting period

the Company's total investment in employee training was RMB
4.2454 million

Employee training coverage rate is
100 %

total training hours reaching
256,575 hours

Employee Rights and Compensation

Governance

Da Ren Tang regards the protection of employee rights and interests as an important component of its corporate governance and human resources management system. Through the integration of institutional development and organizational operations, the Company continuously strengthens the foundation for safeguarding employee rights and interests. The Company strictly complies with relevant laws and regulations, including the *Labor Law of the People's Republic of China* and the *Labor Contract Law of the People's Republic of China*, standardizes labor relationship management, and ensures that employees' legitimate rights and interests are protected in accordance with the law.

The Company continues to improve internal management systems and mechanisms covering compensation and benefits, performance evaluation, trade union operations, employee participation in management, and communication and feedback. These efforts promote transparency in management and collaborative decision-making, and encourage employees to participate in corporate governance and management improvement through multiple channels.

Strategy

The Company adheres to a people-centered development philosophy and is committed to building a fair, transparent, and market-competitive employee rights protection system, promoting the coordinated development of employees and the Company. In 2025, the Company further aligned employee value creation with organizational goals by continuously optimizing compensation, benefits, and performance management mechanisms, gradually establishing a long-term mechanism for shared achievements and collective growth.

Impact, Risk and Opportunity Management

Through systematic measures to safeguard employee rights and interests, Da Ren Tang reduces labor relation risks and employee turnover risks, enhances employee satisfaction and organizational stability, and captures opportunities for management optimization and cultural development brought by deeper employee participation.

Compensation and Benefits

The Company provides employees with competitive salaries in the market and, in accordance with the law, makes full contributions for all employees to pension, medical, work injury, maternity, and unemployment insurance, as well as the housing provident fund. Regular employee health examinations are organized to safeguard employees' physical and mental well-being and reduce occupational health risks.

In terms of performance management, the Company continuously improves a value-contribution-oriented performance evaluation system. Performance contracts are signed with senior management to strengthen accountability and incentive mechanisms, while diversified assessment approaches aligned with job characteristics are implemented for middle- and junior-level employees to ensure fairness and timeliness in incentive distribution.

Employee Communication

The Company has established a scientific and democratic communication mechanism. Employee representative congresses are regularly convened to report annual operational performance and development plans to employee representatives, safeguarding employees' rights to information, participation, expression, and supervision. At the same time, the trade union conducts employee satisfaction surveys to collect employees' opinions and suggestions. Through forums and routine communication, effective and smooth channels are built between employees and the Company.

The Company continues to expand channels for employee communication and feedback. During the reporting period, Chairman Wang Lei opened a direct email mailbox for all employees. The management team regularly holds discussions on key issues related to corporate governance, operational management, and employee concerns to further improve management responsiveness and organizational transparency.



Chairman's email

dongshizhang@jydr.com.cn

Employee Assistance

The Company attaches great importance to providing assistance to employees facing difficulties and offers targeted support through multiple approaches. At the beginning of 2025, the Company issued the "Implementation Opinions of the Trade Union of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd. on the 'Five Inclusive Assistance Mechanisms'", standardizing assistance and inclusive services for employees in need. Additional condolence allowances for model workers were introduced, further improving the employee care system. Meanwhile, the Company carried out dynamic verification of employees in need, major illness assistance, holiday care visits, and special subsidies to provide practical support for employees.

During the reporting period, the Da Ren Tang trade union reviewed applications for major illness assistance on a quarterly basis and continued to organize care activities such as holiday care visits and heatstroke prevention. At the same time, the trade union allocated special subsidy funds to enterprise-level unions and purchased accidental injury and major illness mutual insurance provided by the municipal trade union federation for nearly 4,000 members. Enterprises within the Group were also encouraged to provide An Kang insurance for female employees, further enhancing employees' protection against health and life risks.

Employee Care

Focusing on employees' physical and mental well-being and cultural development, the Company organized various activities such as mental health courses, family care activities, cultural visits, and sports events to enhance employees' sense of belonging and organizational identity.

Case

Cultural Visit Activity for Female Employees

During the reporting period, Da Ren Tang organized a cultural visit activity titled "Celebrating the Spirit of Da Ren Women and Exploring History to Embark on a New Journey" during International Women's Day. A total of 120 female employees from production, marketing, research, and management participated.



Case

Family Month Parent-Child Care Activities

During the reporting period, the Group's trade union organized a series of Family Month activities open to all employees. Four sessions were held, involving 58 employee families and 64 children.




Case Employee Mental Health Lecture Series

During the reporting period, the trade union and the EHS department jointly organized a series of employee mental health lectures in 2025. Experts from Peking University Sixth Hospital, Peking University Hospital, and Tianjin First Central Hospital were invited to deliver courses on topics including "Psychology and Health", "Workplace Stress and Mental Health", "Parenting and Children's Mental Health", and "Caring for Workers' Mental Health". Offline salons and online courses were also arranged to build a diversified platform for psychological support and empowerment. A total of **four** sessions were conducted, with more than **30** hours of courses delivered online and offline, and more than **5,000** person-times of employee participation.



Case Employee Sports Activities and Team Building

During the reporting period, the Company organized the 2025 Employee Sports Meeting, including badminton, table tennis, and billiards competitions to encourage employees to participate in physical exercise. Outstanding athletes were selected to represent the Company in pharmaceutical group competitions and achieved strong results. Meanwhile, the Da Ren Tang football team was re-established and participated in the pharmaceutical group football league, winning second place. **Eleven** outstanding athletes were recommended to participate in the SIIC Group Sports Meeting, and an employee from the No. 6 Chinese Medicine Plant won second place in the table tennis competition.



Indicators and Targets

The Company continues to promote the coordinated advancement of employee rights protection and stable corporate development, with safeguarding employees' legitimate rights and interests and improving employee satisfaction as core objectives. During the reporting period, the labor contract signing rate remained at **100%**, and employees enjoyed various statutory benefits and social security in accordance with the law. Meanwhile, the Company strengthened trade union services and employee communication mechanisms to continuously enhance organizational stability and employees' sense of well-being. In 2025, the Company assisted more than **310** person-times of employees in need, with a total assistance investment of RMB **0.75** million.

Employee Rights	Unit	2025
Labor contract signing rate	%	100
Social insurance coverage rate	%	100
Employee Assistance	Unit	2025
Total person-times of assistance for employees in need	person-times	over 310
Total employee assistance investment	RMB 10,000	75

FY2025 Target	FY2025 Progress
Protect employee rights and interests	<ul style="list-style-type: none"> Determine compensation standards in accordance with national laws and regulations, implement performance evaluations, and ensure employees legally enjoy equal pay for equal work, social insurance and housing provident fund benefits, maternity leave for female
FY2026 Target	Planned Actions
Protect employee rights and interests	<ul style="list-style-type: none"> Determine compensation standards in accordance with national laws and regulations, implement performance evaluations, and ensure employees legally enjoy equal pay for equal work, social insurance and housing provident fund benefits, maternity leave for female employees, and other benefits.



Occupational Health and Safety

Governance

Da Ren Tang incorporates occupational health and safety into its corporate safety governance system and strictly complies with relevant laws and regulations, including the *Law of the People's Republic of China on the Prevention and Control of Occupational Diseases*, the *Work Safety Law of the People's Republic of China*, and the *Tianjin Municipal Regulations on Work Safety*. Relying on the ISO 45001 Occupational Health and Safety Management System, the Company continues to improve a management framework covering responsibility implementation, risk prevention and control, hazard management, and emergency response. The Company continuously implements internal management documents such as the "Safety Production Responsibility System", "Safety Production Reward and Punishment System", "Production Safety Propaganda Education and Training System", "System for the Investigation, Rectification and Management of Potential Hazards in Production Safety Accidents", "Safety Risk Grade Control System", "Emergency Rescue Management System", and "Comprehensive Emergency Plan for Safety Incidents", clarifying the responsibilities of management personnel at all levels and various positions to ensure that occupational health and safety management operates under clear rules and effective control.

As of the end of the reporting period, 6 subsidiaries of the Group have obtained ISO 45001 Occupational Health and Safety Management System certification and remain within the validity period.

Strategy

Da Ren Tang consistently regards employee occupational health and safety as a fundamental safeguard supporting stable operations and high-quality development. Throughout the entire production and operation process, the Company strengthens the management orientation of "prevention first and early risk control". By systematically integrating occupational health requirements into position management, operational protection, and routine inspection processes, the Company promotes the transition of occupational health management from institutional compliance to proactive prevention. Meanwhile, with a focus on enhancing employee safety awareness and emergency response capabilities, the Company continuously strengthens training, drills, and safety culture development to create a safe, healthy, and sustainable working environment.

Impact, Risk and Opportunity Management

In production and operational activities, occupational health and safety not only relate to employees' direct interests but also directly affect the stability of enterprise operations and sustainable development capabilities. For traditional Chinese medicine enterprises, regulatory oversight by national policies continues to strengthen, which may increase compliance costs. Da Ren Tang focuses on key areas such as personnel capability development, on-site risk control, emergency response, and occupational health protection, and continuously implements safety management requirements in daily operations. Through systematic management and continuous improvement, the Company reduces operational risks and enhances organizational stability and resilience.

Personnel Capability Development

The Company continuously strengthens safety training and the operation of the emergency management system. In accordance with the "Production Safety Propaganda Education and Training System", specialized training is organized at different levels and categories for principal responsible persons, safety management personnel, special operation personnel, new employees, and employees transferring to new positions. During the reporting period, Da Ren Tang conducted a total of 259 safety training sessions, covering 10,806 person-times.



conducted a total of **259** safety training sessions

covering **10,806** person-times



Long Shun Rong Pharmaceutical Factory was recognized as a "Safety Culture Development Demonstration Enterprise" in Tianjin

On-site Risk Control

The Company continues to strengthen implementation in risk identification and hazard management, promoting the extension of safety management requirements to operational sites through a combination of routine inspections and special investigations. During the reporting period, Da Ren Tang organized 529 safety inspections, involving 1,574 person-times of inspectors. A total of 637 hazards were identified and rectified, achieving closed-loop management of hazard rectification and effectively reducing the accumulation of safety risks.



Safety inspections

Enhancement of Emergency Response Capability

The Company continues to operate its emergency management system and organizes various emergency drills based on actual production scenarios. In 2025, we organized 265 emergency drills, with 2,317 person-times participating in practical drills, continuously improving employees' emergency response and coordinated handling capabilities.



Scald accident drill



"Emergency Command Center" tabletop simulation



Tianjin 2025 "Ankang Cup" Labor Safety Skills Competition

Occupational Health Protection

The Company continues to organize occupational health examinations and related inspection activities for employees, with particular attention to the health risks of frontline personnel and employees engaged in special operations. Targeted health management measures are implemented according to job characteristics. Through activities such as occupational health public welfare lectures, health science popularization campaigns, and Party-building initiatives empowering safety management, the Company guides employees to strengthen health awareness and improve self-protection capabilities, fostering a safe and healthy working environment and promoting the normalization and refinement of occupational health management.

Case "Occupational Health, You and Me Together" Public Welfare Activity

During the reporting period, Tianjin Pharmaceutical Da Ren Tang Group organized activities for "Occupational Health Promotion Week" and "World Mental Health Day", inviting responsible leaders and department heads from affiliated enterprises to participate. Experts from the Centers for Disease Control and Prevention were invited to provide training on relevant laws and regulations, while physicians from Tianjin First Central Hospital and Da Ren Tang Hospital delivered psychological health education sessions. The EHS department, together with Da Ren Tang Hospital, organized multiple free medical consultations and occupational health public welfare lectures to promote occupational health knowledge and the Company's brand and pharmaceutical products. The Company was awarded the title of Health Enterprise in the Nankai District.



Occupational health public welfare lecture

Indicators and Targets

Da Ren Tang continues to promote the stable operation and expanded coverage of its occupational health and safety management system, maintaining full coverage of safety training and normalized emergency drills, and continuously improving the effectiveness of occupational health and safety management.

During the reporting period, Da Ren Tang adhered to safety red-line management requirements and achieved the safety management targets of zero production safety liability accidents, zero major fire accidents, zero new occupational diseases, and zero administrative penalties.

FY2025 Target	FY2025 Progress	
Work Safety "Four Zeros"	<ul style="list-style-type: none"> Zero production safety liability accidents Zero major fire accidents 	<ul style="list-style-type: none"> Zero new occupational diseases Zero administrative penalties
FY2026 Target	Planned Actions	
Work Safety "Four Zeros"	<ul style="list-style-type: none"> Conscientiously carry out risk identification and assessment to ensure 100% implementation of control measures; Actively conduct safety training to ensure 100% safety training coverage; Promote the establishment of the "dual-control" mechanism for safety risk grading control and hazard investigation and management, achieving 100% coverage of the "dual-control" mechanism across all enterprises. 	

04 Adhering to Pharmaceutical Integrity and Forging the Quality of Da Ren Tang

R&D Innovation Enhancement	79
Quality and Safety Assurance	82
Customer Rights and Interests Protection	91
Supply Chain Management Improvement	95



- Product Quality and Safety
- Supply Chain Management
- Research and Innovation
- Customer Rights and Privacy Protection

Da Ren Tang consistently applies rigorous standards to every stage of production and management, taking safety, reliability, and stability as the core requirements of its products and services. Through continuously optimizing management processes and quality control mechanisms, the Company ensures standardized operations throughout the entire lifecycle from research and development to delivery, providing customers and society with reliable health products over the long term. At the same time, the Company actively embraces opportunities arising from technological progress and industrial upgrading, strengthening compliance management and data security awareness while promoting innovative applications, and continuously enhancing its governance capabilities and operational quality to consolidate the foundation for steady corporate development.



Research and Innovation


Da Ren Tang adheres to scientific and technological innovation as a key driver for the high-quality development of traditional Chinese medicine and regards the enhancement of research and development capabilities as an important support for strengthening core competitiveness and serving public health. Focusing on the inheritance and innovation of traditional Chinese medicine and the prevention and treatment of major diseases, the Company continuously improves its R&D governance system, carries out systematic research in key areas, and promotes the transformation of research outcomes into clinical and industrial value, supporting the modernization and sustainable development of traditional Chinese medicine.

R&D Innovation Management System

The Company has formulated institutional documents including the "Specialized Management System for Scientific Research of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", the "Specialized Management System for Project Approval of Scientific Research Projects of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", and the "Specialized Management System for the Process of Scientific Research Projects of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.", standardizing the full lifecycle management process of research projects from project initiation and feasibility review to implementation and final acceptance, thereby ensuring the orderly advancement of R&D activities.

At the same time, the Company has established a clearly defined and highly collaborative R&D organizational structure composed of the Da Ren Tang Technology Center, the Institute of Traditional Chinese Medicine Research, and the production enterprises under Da Ren Tang, effectively supporting the implementation of R&D projects.

R&D strategic positioning: Leader in Modern Traditional Chinese Medicine



Scientific Research Platforms and Talent Support

As a National High-Tech Enterprise and a National Intellectual Property Demonstration Enterprise, Da Ren Tang possesses a national-level enterprise technology center and several provincial and municipal innovation platforms. The Company has also established an Academician Expert Workstation, a Postdoctoral Research Workstation, and a CNAS-accredited testing laboratory, continuously attracting and cultivating high-level scientific research talent. In 2025, Da Ren Tang and its subsidiary Jingwanhong Pharmaceutical were recognized as "Leopard Enterprises" in Tianjin, further affirming their technological innovation capabilities.

Scientific research platforms include 1 national-level enterprise technology center, 6 municipal-level enterprise technology centers, 1 Tianjin Engineering Center for the Modernization of Traditional Chinese Medicine Technology, and 1 Tianjin Key Laboratory for Quality Control of Traditional Chinese Medicine.

We attach importance to the cultivation and incentive mechanisms for scientific research talent. Relying on the "Special Management System for the Tianjin Pharmaceutical Scientific Research Innovation Award", the Company has established a multi-dimensional incentive system covering projects, products, patents, and talents, placing emphasis on long-term incentives and support for core researchers and teams, and encouraging breakthroughs in key technologies and core product varieties.

Intellectual Property Protection

The Group incorporates intellectual property protection and the commercialization of research outcomes into its R&D management system. By improving patent layout and achievement management mechanisms, the Company safeguards the legitimate rights and interests of independently developed results and promotes standardized transformation and continuous application of research outcomes.

Key R&D Achievements

In 2025, the Group achieved positive progress in new product development, participation in major scientific research projects, and technological innovation.

New product development | A total of 7 new products were approved for market launch, including loxoprofen sodium gel patches; the "Shuren Anfu" series of cosmetic products, including facial masks, creams, and sprays; Meiyun Runfei Drink; Qushi Xiaozhi Drink; and 3 health products registered in Macao, namely Da Ren Anshen Wan.

National major science and technology projects | As of the end of 2025, Da Ren Tang had participated in and obtained approval for 9 national major science and technology projects and 14 sub-projects under the national program "Research on the Prevention and Treatment of Cancer, Cardiovascular and Cerebrovascular Diseases, Respiratory Diseases and Metabolic Diseases". 7 exclusive products were selected, including Suxiao Jiuxin Wan, Shenfu Qiangxin Wan, Qingfei Xiaoyan Wan, Jingwanhong Ointment, Jinqi Jiangtang Tablets, Zilongjin Tablets, and Yifei Qinghua Ointment.

Secondary development of major traditional Chinese medicine products | Through real-world studies and clinical trials, the clinical advantages of products such as Suxiao Jiuxin Wan and Qingyan Dripping Wan were further verified, and related research outcomes were incorporated into clinical diagnosis and treatment guidelines and emergency procurement catalogs.

Advancement of modified innovative drug research | Exploratory research projects were initiated to investigate additional indications for 3 major traditional Chinese medicine products, namely Biqi Capsules, Jingwanhong Ointment, and Shenfu Qiangxin Wan, supporting the expansion of clinical applications and improving convenience in medication use.

Digital and intelligent empowerment | Digital and intelligent technologies, such as machine vision and digital twins, were applied to empower production process control, improving quality, stability, and production efficiency.



A total of **7** new products were approved for market launch

Da Ren Tang had participated in and obtained approval for **9** national major science and technology projects

14 sub-projects

Launched **3** exploratory research projects on new indications for major traditional Chinese medicine products

Based on changes in disease patterns and aging trends, the Group focuses its R&D layout on chronic disease areas such as cardiovascular and cerebrovascular diseases and metabolic diseases. The Company actively participates in research related to the "four major chronic diseases", continuously exploring the mechanisms and application pathways of traditional Chinese medicine in chronic disease prevention, treatment, and integrated management.



"Evidence-based Evaluation and Mechanism Research on Multi-metabolic Disorders in Elderly Diabetes" project



"Clinical Efficacy Observation of Electroacupuncture Combined with Immune Checkpoint Inhibitors for Postoperative Adjuvant Treatment of Early-stage Non-small Cell Lung Cancer" sub-project



"Construction of an Artificial Intelligence-based Integrated Diagnosis and Treatment Management System for Pulmonary Nodules Combining Traditional Chinese and Western Medicine and Research on Key Technologies" project

During the reporting period, the Company's R&D and innovation achievements received multiple scientific and technological awards. Da Ren Tang was included in the "2025 China Traditional Chinese Medicine R&D Strength Top 50", the project "Secondary Development and Application of the Major Variety Longqing Tablets" received the Third Prize of the 2024 Tianjin Science and Technology Progress Award, and the "Zhang Chengui Modern Traditional Chinese Medicine Preparation Technology Innovation Team" received the 2025 Science and Technology Award of the China Association of Traditional Chinese Medicine – Huatuo Traditional Chinese Medicine Award.

In 2025, the Company's total R&D investment amounted to RMB 204.0602 million, with a total of 113 R&D personnel. A total of 29 new patents were granted during the year. The number of valid intellectual property rights is as follows:

Intellectual Property	Unit	2025	
Total number of valid patents/ trademarks of the Company	Invention patents	Pieces	241
	Utility model patents	Pieces	76
	Design patents	Pieces	90
	Number of published papers	Pieces	36
	Trademarks	Pieces	1,668

Technology Ethics

During the conduct of scientific research activities, Da Ren Tang always regards technological ethics and respect for life as essential prerequisites for R&D governance. The Company strictly complies with laws and regulations, including the *Drug Administration Law of the People's Republic of China*, the *Regulations on the Administration of Human Genetic Resources of the People's Republic of China*, the *Regulations on the Administration of Laboratory Animals*, and the *Guiding Opinions on the Humane Treatment of Laboratory Animals*. A technology ethics management system centered on ethical review and emphasizing both animal welfare and biosafety has been established and implemented to systematically manage the compliance and ethical integrity of research activities.

The Company has formulated and implemented institutional documents, including the "Charter of the Laboratory Animal Ethics Committee of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd." and the "Safeguard Measures for Animal Welfare and Biosafety of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd.". A Laboratory Animal Ethics Committee has been established to conduct prior review and ongoing supervision of scientific research projects involving laboratory animals. All proposed animal experiment projects must submit the "Animal Experiment Ethics Review Form of Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd." before implementation. The Committee conducts a comprehensive evaluation from multiple dimensions, including experimental necessity, animal welfare, biosafety, and ethical compliance, and relevant research may only proceed after approval.

In research practice, the Company incorporates animal welfare requirements throughout the entire process of experimental design and implementation, adhering to the "3R" principles of replacement, reduction, and refinement. Alternative methods such as mathematical models, computer simulations, and in vitro experiments are prioritized to reduce the need for live animal use. When the use of laboratory animals is unavoidable, the Company minimizes the number of animals used and potential experimental harm through scientific selection of animal strains and grades, optimization of experimental plans, and improvement of operational procedures. During experiments, anesthesia and analgesia measures are uniformly adopted to control pain responses, and professional personnel provide full-process supervision. After experiments, animals are handled humanely to avoid unnecessary stress and risk.

During the reporting period, all scientific research projects involving laboratory animals at Da Ren Tang were implemented in accordance with ethical review procedures, and no violations of technology ethics, animal welfare, or biosafety requirements occurred.

Quality and Safety Assurance

Product Quality and Safety

Governance

The Da Ren Tang Group has always regarded product quality and safety as the lifeline of corporate development. Centered on the quality mission of "risk prevention and control, quality improvement and efficiency enhancement, and brand promotion", the Group has built a digital and intelligent "TCM full industry-chain traceability" quality management model and a three-tier quality management system at the Group level, covering all business formats, the full industry chain, and the full product lifecycle. The Company strictly complies with laws and regulations such as the *Drug Administration Law of the People's Republic of China*, the *Good Manufacturing Practice for Drugs (GMP)*, and the *Administrative Measures for Drug Registration*. In line with different business formats, it has formulated and continuously improved institutional documents covering quality management, quality risk management, market complaints and recalls, pharmacovigilance and safety, among others, forming a quality governance framework with clear responsibilities and closed-loop processes, and providing strong safeguards for quality and safety management.

Quality System Development

The Group has established a pharmaceutical quality assurance system aligned with both domestic and international requirements, supporting compliant product registration, manufacturing, and sales. As of the end of the reporting period, the certified and accredited quality systems are as follows:

- With Da Ren Tang Group as the entity, 2 sites (Binhai Industrial Park and Anguo pre-processing workshop) and 4 dosage forms (tablets, granules, pills, and hard capsules) have obtained Australia TGA certification, supporting compliant international sales in more than 20 countries, including Australia, Canada, and the UK, that apply regulations of the Pharmaceutical Inspection Co-operation Scheme (PIC/S);
- 31 products from 5 pharmaceutical manufacturing entities of the Group (Long Shun Rong Pharmaceutical Factory, Darentang Pharmaceutical Factory, Le Ren Tang Pharmaceutical Factory, No. 6 Chinese Medicine Plant, and Jingwanhong Pharmaceutical) have obtained Indonesia HALAL international certification, and the certificates are recognized by 24 countries, including Singapore, Malaysia, the Philippines, Thailand, Japan, and Australia;
- Le Ren Tang Pharmaceutical Factory has obtained Japan PMDA certification;
- NewScen Coast has obtained EU CE certification for 7 medical device products;
- The Chuanxiong GAP Planting Base and the Honeysuckle (decoction pieces) GAP Planting Base have passed the extension inspection by the Tianjin drug regulatory authority.
- 9 pharmaceutical manufacturing entities and 1 medical device entity of the Group all possess GMP qualifications, and can produce qualified Chinese medicinal decoction pieces, Chinese patent medicines, chemical drugs, and medical device products in accordance with registered processes and quality requirements, ensuring quality and quantity to meet market and consumer needs;
- NewScen Coast medical devices have obtained ISO 9001 and ISO 13485 quality management system certifications;
- The Da Ren Tang Group Testing Center has obtained CNAS accreditation from the China National Accreditation Service for Conformity Assessment (CNAS), with 145 accredited parameters;
- 4 pharmaceutical manufacturing entities of the Group (Darentang Pharmaceutical Factory, Long Shun Rong Pharmaceutical Factory, Le Ren Tang Pharmaceutical Factory, and No. 6 Chinese Medicine Plant) have obtained ISO 10012 measurement management system certification.

Quality Inspection Overview

During the reporting period, the Group's affiliated entities successfully passed multiple inspections by domestic and overseas regulators. We use inspections to drive improvement, identify shortcomings in quality management, close the loop on rectifications, and continuously enhance the standardization and effectiveness of the quality management system.

- With Da Ren Tang Group as the entity, Long Shun Rong Pharmaceutical Factory and Darentang Pharmaceutical Factory, as formulation centers, passed the Australia TGA certification inspection.
- 31 products from 5 pharmaceutical manufacturing entities (Long Shun Rong Pharmaceutical Factory, Darentang Pharmaceutical Factory, Le Ren Tang Pharmaceutical Factory, No. 6 Chinese Medicine Plant, and Jingwanhong Pharmaceutical) passed the on-site inspection for Indonesia HALAL certification.
- NewScen Coast's HIV card-type colloidal gold reagent passed the on-site system audit for CE certification.
- The Honeysuckle (decoction pieces) GAP Planting Base passed the extension inspection by the Tianjin drug regulatory authority.
- The Group Testing Center passed the CNAS on-site re-assessment.
- The Group's manufacturing entities underwent a total of 35 GMP inspections by drug regulatory authorities, all of which were passed. 9 manufacturing entities completed renewal of their *Drug Manufacturing License* upon expiration.
- The Group's commercial entities underwent a total of 9 GSP inspections by drug regulatory authorities, all of which were passed.
- The Group's manufacturing entities underwent a total of 3 GVP inspections by drug regulatory authorities, all of which were passed.

Product Innovation and Technology Upgrades

To maintain core product competitiveness, the Group advances product innovation and technology upgrades through new product introduction and upgrades of existing products. Key project outcomes during the reporting period include:

- Xinxin Pharmaceutical Plant obtained approval for the Class 4 chemical generic drug "Loxoprofen Sodium Gel Patch";
- NewScen Coast independently developed and obtained approval for the Class II medical device "25-Hydroxyvitamin D Test Kit";
- 14 products obtained international registration in Singapore, supporting international market expansion;
- Through process and quality improvement and stability studies, 7 products, including Yifei Qinghua Ointment, Huanglian Shangqing Tablets, and Fangfeng Tongsheng Wan, extended shelf life from 24 months to 36 months, effectively enhancing product market performance;
- Through process technology research, "Shaofu Zhuyu Wan" added a "small honeyed pill" specification, which was approved by the NMPA CDE, improving patient medication experience;
- Through advanced technologies such as AI, near-infrared spectroscopy, machine vision, and digital twin, the Group achieved intelligent transformation of mass production and quality control for the core product "Suxiao Jiuxin Wan" and established an intelligent manufacturing production base for Suxiao Jiuxin Wan.


Strategy

Da Ren Tang Group, aligned with public medication safety and the requirements for high-quality industry development, positions quality, safety, and development as a long-term quality strategy. By strengthening quality system management capabilities, advancing quality technology innovation, and fostering a culture of continuous quality improvement with full participation, the Group continuously enhances its resilience to quality risks throughout operations and ensures safe, stable, and sustainable product supply.

At the same time, in line with the Group strategy of "Winning by Quality, Winning the Future by Quality", we empower brand building through quality, deeply integrating quality management into business and market expansion, and continuously enhancing consumer trust and the brand's social credibility.


Digital and Intelligent Leadership

- The "digital and intelligent 'TCM full industry-chain traceability' quality management model" innovatively developed by Da Ren Tang Group won the top award of the "Sixth Tianjin Quality Award", which is the highest commendation of the Tianjin Municipal Government for enterprises leading in quality, technological innovation, brand excellence, and outstanding performance.





- Da Ren Tang Group's "full-process traceability of TCM quality" achievements won the "2024 Quality Craftsmanship Achievement" in the national pharmaceutical industry for its breakthrough innovation in TCM quality control.



- Da Ren Tang Group innovated the reading format of drug package inserts, and through a self-built information platform, successfully realized multiple age-friendly functions such as "digital avatar video + e-insert + voice broadcast".
- Chuanxiong, the raw material for "Suxiao Jiuxin Wan" at No. 6 Chinese Medicine Plant, passed the extension inspection for Tianjin GAP Planting Base in 2024. In 2025, the packaging label added the statement "medicinal materials comply with GAP requirements". The label change was filed and approved by the Tianjin drug regulatory authority, and completed the transition to the new packaging on the market, making it the first oral solid TCM preparation in Tianjin with the statement "medicinal materials comply with GAP requirements".



Quality Culture Development

The Da Ren Tang Group attaches great importance to quality culture development. Based on four key dimensions—regulatory training, process improvement initiatives, activity empowerment, and government–enterprise collaboration—we cultivate a shared quality consensus across all employees through systematic and diversified measures, shaping a positive quality culture atmosphere and ensuring compliant and sustainable development of the Group's century-old brand.

- **Government–enterprise collaboration led by senior management, demonstrating the broader pattern of quality responsibility culture**

Da Ren Tang Group's senior management, based on the quality strategy, incorporates government–enterprise collaboration into the overall quality culture framework, leading participation in collaborative efforts on drug regulatory policies, deeply engaging in consultations on policies and regulations, and proactively aligning with authoritative industry institutions to deepen cooperation. Through projects, we conduct in-depth cooperation with universities, research institutes, regulatory authorities, and industry associations, focusing on quality culture inheritance of time-honored TCM brands and seeking innovation leadership with the times, to strengthen the public medication safety defense line.

- **Regulatory training as a cradle for cultivating a compliance culture, strengthening policy alignment capability across positions**

During the reporting period, the Group and its affiliated entities closely followed regulatory updates and supervisory orientation, and systematically carried out special studies on the *Pharmacopoeia of the People's Republic of China (2025 Edition)* and the *Special Provisions on the Supervision and Administration of TCM Production*, conducting in-depth interpretation of clauses and assessment of industry trends, while upgrading the Group's quality system development to ensure that the capabilities of personnel in all positions remain aligned with the latest policy requirements.

● **Process and quality improvement initiatives as a lever to unite all employees in building a culture of continuous improvement**

During the reporting period, the Group's affiliated entities targeted quality pain points and challenges in production and operations, and implemented 87 key process and quality improvement projects. The outcomes contributed to quality improvement and efficiency enhancement of approximately RMB 14 million. The project "R&D of a New Standard for Suxiao Xintong Dripping Wan", won the Tianjin Outstanding Quality Improvement Achievement Award. 14 QC group outcomes participated in the 46th National Pharmaceutical Industry QC Group Outcome Presentation; 10 outcomes won "First-Class Outcome" awards and 4 outcomes won "Excellent Outcome" awards, forming a strong atmosphere of full participation and continuous improvement. These efforts created significant economic benefits and drove continuous improvement in product quality and consumer satisfaction.

● **Diverse activities as a bond to deepen quality culture communication, stimulating full participation, and a sense of quality responsibility**

Taking the application for the Sixth Tianjin Quality Award as an opportunity, the Group called on all employees to participate, consolidating the consensus of "Everyone Values Quality" and strengthening the foundation for quality culture development. In September, we launched Quality Month activities themed "Strengthening Source Quality, Responsibility Control and Focusing on Compliance Quality System Development". We conveyed quality concepts through the "AI Draws Quality" poster competition and strengthened frontline quality awareness through the second "QC Technical Skills Competition". The Group actively participated in industry exchanges; 5 managers received industry commendations. We participated for the first time in the Pugongying Pharmaceutical Industry Annual Debate Competition and won both the "Most Exciting Session" and "Most Popular Team" awards. We consolidated quality concepts through distinctive internal activities and stimulated full participation through external honors, comprehensively building a cohesive force for the Group's quality culture.



"AI Draws Quality" innovative poster design competition



Participation in the 15th Pugongying Pharmaceutical Industry Debate Competition



Da Ren Tang Group's 2nd QC Skills Competition



Participation in the National Pharmaceutical Industry QC Group Outcome Presentation

Impact, Risk and Opportunity Management

Da Ren Tang Group advances systematic quality and safety risk prevention and control, and continuous improvement from multiple dimensions, including risk identification, process control, technology enablement, and capability development, reducing operational and product quality risks, while supporting high-quality development opportunities through technological progress and management enhancement.

Quality Risk Management

Based on the ICH Q9 risk management principles, the Group formulated and implemented the "Quality Risk Management Procedures" and the "Quality Risk Alert Management System", covering the full process from raw material procurement, manufacturing, testing, distribution, and after-sales. Quality risk assessments are carried out through a combination of proactive and retrospective approaches, clarifying risk control measures and responsibility allocation, and promoting a shift in quality risk management from post-incident handling to pre-incident prevention. The Group Quality Management Department leads affiliated entities each year to conduct quality-related risk and hidden hazard inspections, and initiates process and quality improvement projects for issues with potential risks, implementing "dynamic close-out" management.

Strengthening Source Quality Control

The Group Quality function conducts unified evaluation to standardize the Group-wide centralized procurement quality standards for TCM raw materials across affiliated entities, specifying that 46 TCM raw materials (51 internal control standards) are higher than the *Pharmacopoeia of the People's Republic of China*. The Group ensures source supply quality through medicinal material planting base development, completing construction of 2 GAP Planting Bases for Chuanxiong and Honeysuckle and passing the GAP extension inspection by Tianjin drug regulatory authority; completing construction of 6 "Three-No and One-Complete" bases for Chuanxiong, Honeysuckle, Wuweizi, Huanglian, Houpu, and Banxia; and achieving source procurement quality traceability for 37 varieties including Chuanxiong and Honeysuckle, covering 40% of the core TCM raw materials under centralized procurement. The Group formulated the *Tianjin Pharmaceutical Da Ren Tang Joint Audit Management System for Centralized Procurement Suppliers of TCM Raw Materials*, and has completed coordinated on-site joint audits for 34 centralized procurement source suppliers of TCM raw materials, ensuring source quality control and GMP compliance.

specifying that 46 TCM raw materials (51 internal control standards) are higher than the <i>Pharmacopoeia of the People's Republic of China</i>	completing construction of 2 GAP Planting Bases	completing construction of 6 "Three-No and One-Complete" bases
achieving source procurement quality traceability for 37 varieties	covering 40% of the core TCM raw materials under centralized procurement	and has completed coordinated on-site joint audits for 34 centralized procurement source suppliers of TCM raw materials

Strengthening Group Internal Audit and Contract Manufacturing Access Audit

The Group Quality function carries out multi-level and differentiated quality audit work for pharmaceuticals and health products based on different business entities and key risk points. For pharmaceuticals, this mainly includes Group internal audits based on GAP/GMP/G-SP/GVP and special internal audits conducted by professional third-party firms. Issues identified are rectified in a timely manner to ensure compliant operation and continuous improvement of the Group quality system. For the Group's new health-product business formats, the "Quality Management Standards for Outsourced Production, OEM, and ODM Production of Health Products" was formulated. The Group has completed on-site audits and access evaluations for 84 contracted entities for health products, and included qualified entities in the Group's contracted-entity database to support related outsourcing cooperation. The Group strengthens on-site audit management, using real dynamic inspections to ensure quality controllability and compliance, and to avoid operational quality risks.

Pharmacovigilance Management

The Group Quality function continues to strengthen monitoring and analysis of adverse drug reactions and related safety information, and promptly identifies potential medication risks. We strictly comply with the national *Good Pharmacovigilance Practice (GVP)* requirements, embedding pharmacovigilance responsibilities throughout the full lifecycle of drug R&D, manufacturing, marketing authorization, and use. We have realized an in-depth application of the pharmacovigilance PV information system, enabling unified collection, dynamic tracking, and closed-loop management of adverse drug reactions and related information, continuously improving the standardization and operational efficiency of pharmacovigilance.

Da Ren Tang Group attaches great importance to patients' medication safety and actively fulfills the principal responsibilities of MAH (Marketing Authorization Holder). We strictly comply with the *Special Provisions on TCM Registration* issued by the National Medical Products Administration and continuously improve safety information in TCM product package inserts. During the reporting period, we conducted scientific evaluation and substantiation of key safety information, such as "Adverse Reactions", "Contraindications", and "Precautions", completed safety information revisions for 119 product package inserts, and submitted them to the NMPA CDE. As of the end of the reporting period, 68 products have been approved.

completed safety information revisions for

119

product package inserts, and submitted them to the NMPA CDE

As of the end of the reporting period ,

68

products have been approved

Emergency Recall Mechanism

The Da Ren Tang Group Quality function strictly implements GMP-compliant management and MAH principal responsibilities, and has established the "Drug Recall Management System", clarifying emergency handling mechanisms for quality and safety risks and incident reporting procedures. Entities regularly organize mock recall drills to enhance response capabilities for sudden quality incidents. During the reporting period, the Group had no drug quality recall incidents.



Indicators and Targets

Da Ren Tang Group, guided by improving product quality, stability, and safety, continues to incorporate quality improvement outcomes into the management target system.

Our annual targets and progress are as follows:

FY2025 Target	FY2025 Progress
"Customer-centered" approach to meet patients' medication consumption needs in the new era	<ul style="list-style-type: none"> Innovatively established the "Digital and Intelligent TCM Full Industry Chain Traceability" quality management model, providing new medication experiences for consumers in the new era; In 2025, the product quality complaint rate decreased to 1.20 per million, lower than the industry average; Age-friendly electronic package inserts for 6 products were launched in the market to meet the medication needs of the elderly and other special groups.
Establishing a comprehensive international sales quality assurance system	<ul style="list-style-type: none"> Da Ren Tang Group obtained Australia TGA certification; 31 products from 5 pharmaceutical manufacturing subsidiaries of the Group obtained Indonesia international HALAL certification; NewScen Coast's HIV card-type colloidal gold reagent passed the on-site system audit for CE certification; Le Ren Tang Pharmaceutical Factory obtained Japan PMDA certification; 26 products obtained international registrations in Singapore and other countries and regions.
Optimizing product processes, improving product standards or safety information, and enhancing product market competitiveness	<ul style="list-style-type: none"> During the reporting period, 7 products completed stability studies, extending shelf life from 24 months to 36 months; Studies were initiated for 8 products to add a small honeyed pill dosage form; during the reporting period, Shaofu Zhuyu Wan obtained NMPA approval for adding the small honeyed pill specification, improving the patient medication experience; The new <i>Pharmacopoeia of the People's Republic of China (2025 Edition)</i> will take effect on 1 October 2025, with 4,029 quality standards revised or formulated to ensure product quality, safety, and compliance; Product processes were optimized, quality indicators improved, and 546 products completed compliant re-registration.
FY2026 Target	Planned Actions
Upgrading the quality management system and strengthening the Group's quality control capabilities	<ul style="list-style-type: none"> In accordance with the new regulations of the <i>Special Provisions on the Supervision and Administration of TCM Production</i>, establish a Group-wide unified quality management system and build a matrix-based Group quality management structure; Implement quality information systems/tools (DMS/TMS/QMS/LIMS) to connect unified process control across the Group and subsidiaries and strengthen record and data traceability through digital management; Establish and improve the Group GxP inspection team to meet multi-dimensional audit needs in quality management and strengthen compliance management;
Consumer-centered promotion of product, process, and quality improvement projects to enhance product market competitiveness	<ul style="list-style-type: none"> Promote the resumption of production of dormant products to ensure drug supply; Implement dosage form improvements by converting large honeyed pills into small pills, improving patient medication experience; Conduct drug stability studies to extend product shelf life; Add stick-pack packaging to provide consumers with a more convenient medication experience; Scientifically revise safety information in product package inserts to ensure patient medication safety;
Actively participating in and leading the upgrading of industry standards and specifications	<ul style="list-style-type: none"> Lead or participate in the formulation of national, industry, and association standards, leveraging the leadership role of the time-honored brand in the industry.

Customer Rights and Privacy Protection

Governance

Da Ren Tang regards the protection of customers' legitimate rights and interests as an important foundation for stable operations and brand development. Focusing on customer service quality and information security protection, the Company has established a systematic governance framework. In terms of customer service, the Group has established a unified and professional customer service center responsible for the after-sales services of pharmaceutical production and distribution businesses across the Group. The Company has formulated and implemented institutional documents such as the "After-Sales Service Management System of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited" and "Quality Complaint Management System of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited", forming a full-process e-commerce customer service management mechanism that clarifies service standards, responsibilities, and problem-handling requirements. In terms of customer information and privacy protection, the Company has formulated and implemented the "E-commerce User Data Security Management Provisions of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited", regulating the collection, storage, use, and management of customer data. Distributors and relevant partners are also required to sign confidentiality agreements to prevent customer information security risks at the institutional level.

Strategy

Adhering to the service philosophy of "customer first", Da Ren Tang continuously promotes the standardized and digital development of its customer service system and information security management, intending to improve customer satisfaction and trust. By improving complaint response mechanisms, strengthening employees' professional capabilities, introducing intelligent service tools, and enhancing customer privacy protection management simultaneously, the Company continuously optimizes the customer experience, reduces service and information security risks, and promotes the long-term and stable development of customer relationships.

Impact, Risk and Opportunity Management

Da Ren Tang systematically identifies potential risks in key areas such as customer service operations, medication information communication, and customer information security, and continuously improves management measures to ensure the effective implementation of customer rights protection and enhance the effectiveness and sustainability of such protection.

Customer Service and Complaints

Da Ren Tang Group implements refined classification management of after-sales services. Service categories are clearly divided into consultation calls, feedback and suggestions, quality complaints, and ADR complaints, forming a classified and standardized efficient handling and management mechanism to ensure that different types of after-sales requests are responded to accurately and handled professionally. In 2025, a total of 181 quality complaints were handled, with a resolution rate of 100%, achieving full-process closed-loop management of after-sales services and ensuring that customers' legitimate requests are resolved in a timely manner.

At the same time, the Company places great emphasis on the closed-loop management of product quality complaints. For complaints confirmed through investigation to be related to product quality defects, dedicated improvement projects are initiated to resolve the issues and prevent the recurrence of similar complaints. In 2025, the Group's product quality complaint rate decreased to 1.20 per million, representing a year-on-year decrease of 37.8% compared with 2024. Product quality, stability, and reliability were further improved, and the special quality control initiatives achieved notable results.

In e-commerce services, Da Ren Tang has established a full-process customer service mechanism covering pre-sales consultation, in-process follow-up, and after-sales services, and has set up dedicated customer service and complaint channels on platforms such as Tmall and JD.com. Customer complaints are incorporated into a unified closed-loop handling process to ensure traceability and reviewability of problem resolution, effectively reducing customer risks arising from delayed responses or improper handling.



Customer contact channels



The Company actively applies digital technologies to enhance service efficiency and accuracy through the CRM system and intelligent customer service robots. At the same time, a standardized quality complaint handling process has been established and implemented to ensure that the acceptance, investigation, handling, and improvement of customer feedback related to product quality are fully traceable. The Company's "Digital Customer Service System" integrates manual customer service, 24-hour online services, and AI robot-assisted services, realizing intelligent and convenient after-sales services.

Functions of the digital customer service system



Improvement of customer satisfaction

Da Ren Tang Group regularly conducts customer satisfaction assessments to continuously optimize product quality and service standards while providing data support and customer perspectives for strategic decision-making. Focusing on three core customer groups—consumers, doctors, and pharmacy staff—the Group conducts multi-dimensional and stratified sampling customer satisfaction research. The overall average score reached 9.1 (out of 10), demonstrating the effectiveness of the Group's efforts in improving product quality, upgrading customer services, and providing a solid data foundation for further enhancing customer experience and customer rights protection.

The Group conducts multi-dimensional and stratified sampling customer satisfaction research show a overall average score reached

9.1

In addition, the Company conducts surveys through e-commerce platform evaluation systems and quarterly questionnaires. The results are used to optimize service processes, improve training content, and refine management systems, thereby continuously improving service quality. During the reporting period, the Company's e-commerce customer satisfaction rate reached 96.2%.

During the reporting period, the Company's e-commerce customer satisfaction rate reached

96.2%

Consumer privacy protection

During business operations, the Company implements classified management and access control for customer information, regulates data usage scenarios, and prevents risks of information misuse or leakage. At the same time, by requiring distributors to sign confidentiality agreements, the Company extends the responsibility boundary of customer information security management and enhances the overall level of data security. During the reporting period, no data security or privacy leakage incidents occurred.

Strengthening service capabilities

The Company places customer health and medication safety at the core of its operations and embeds relevant safeguard mechanisms throughout the entire product chain, including product design, production, sales, and services. A dedicated team of licensed pharmacists provides professional medication guidance, and a mechanism for the collection and feedback of adverse drug reactions (ADR) has been established to ensure timely reporting and follow-up handling, thereby safeguarding patient medication safety. Relevant measures for medication safety protection are detailed in the "[Pharmacovigilance Management](#)" section, and initiatives to improve patient medication experience are described in the "[Meeting the Needs of Specific Groups](#)" section.

During the reporting period

4 customer service training sessions were conducted

achieving a training coverage rate of

100%

Indicators and Targets

The Company continues to strengthen customer service management by setting annual targets around key indicators such as customer satisfaction, complaint response, and service efficiency, while establishing monitoring and evaluation mechanisms. By regularly collecting customer feedback, analyzing service data, and optimizing management processes, the Company continuously improves service quality and enhances customer experience.

During the reporting period, the Group's customer service center achieved a problem resolution rate of 100%. Customer complaint response time was controlled within 2 hours, and service quality remained stable.

During the reporting period,

the Group's customer service center achieved a problem resolution rate of

100%

Customer complaint response time was controlled within

2 hours

Our annual targets and progress are as follows:

FY2025 Target	FY2025 Progress
Improve customer satisfaction and respond to customer requests	<ul style="list-style-type: none"> E-commerce customer satisfaction rate: 96.2%; Complaint response time ≤ 2 hours, resolution rate 100%; Product quality complaint rate: 1.20 per million.
FY2026 Target	Planned Actions
Improve customer satisfaction and respond to customer requests.	<ul style="list-style-type: none"> Continue to improve the after-sales service management system and promote intelligent upgrades of the customer service system. Optimize institutional procedures and complaint determination standards, and improve the handling mechanism for complex complaints. Enhance the comprehensive service capabilities of customer service personnel through exchanges with advanced enterprises, regular training, and the sharing of classic case studies. Clarify quality responsibility boundaries, distinguish causes between production and circulation stages, implement classified control, and strengthen closed-loop management of complaint issues.

Strengthening the Management System

Da Ren Tang continuously improves its integrated supply chain management system to ensure product quality stability, the supply of key raw materials, and supply continuity. Compliance requirements, green principles, and digital capabilities are embedded throughout the entire supply chain operation, promoting the supply chain system to steadily evolve toward greater standardization, transparency, and sustainability. The Company has formulated and implemented internal regulatory documents such as the "Qualification Audit Management System for Supply Units of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited", the "Construction of High-Quality Authentic Medicinal Material Bases, Traceability, and Supplier Management System of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited", and the "Detailed Rules for Supplier Inspection and Evaluation of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited". These documents regulate supplier access, evaluation, changes, and elimination through full-process management, ensuring compliance and quality control of procurement and supply chain operations from the source.

Supplier Evaluation and Management

During supplier access and dynamic evaluation, the Company has established a multi-dimensional sustainability evaluation mechanism. On-site inspections are conducted for potential and newly introduced suppliers, with a focus on their performance in environmental management, labor protection, occupational health and safety, and business ethics. Under equivalent conditions, suppliers with strong environmental performance and social responsibility practices and those that have obtained authoritative certifications such as ISO14001 and ISO45001 are given priority for inclusion in the qualified supplier list and cooperation opportunities. This approach encourages upstream and downstream partners to practice responsible operations and continuously enhance the resilience and sustainability of the supply chain.

At the same time, the Company implements a centralized review mechanism for production material suppliers, focusing on their quality management systems, EHS qualifications, as well as energy management and water conservation performance. Corporate culture and compliance requirements are also communicated during the review process to encourage continuous supplier improvement. The Group has formulated the "Joint Audit Management System for Centralized Procurement Suppliers of TCM Raw Materials of Tianjin Pharmaceutical Da Ren Tang", and has completed joint on-site audits of 34 centralized procurement suppliers of Chinese medicinal raw materials to ensure source quality control and GMP compliance. In addition, the "Quality Management Standards for Outsourced Production, OEM, and ODM Production of Health Products" has been established. On-site audits and access assessments have been completed for 84 entrusted enterprises producing health products, and qualified enterprises have been included in the Group's entrusted enterprise database to support commissioned cooperation.



The Group has completed joint on-site audits of **34** centralized procurement suppliers of Chinese medicinal raw materials to ensure source quality control and GMP compliance



On-site audits and access assessments have been completed for **84** entrusted enterprises producing health products



During the reporting period, the Group continued to optimize its supplier structure. The total number of suppliers reached 648, including 346 medicinal material suppliers. Among them, 45 new suppliers were added, 5 suppliers failing to meet internal control standards were eliminated, and 9 suppliers were reviewed. There were also 302 suppliers of excipients and packaging materials, with 14 new suppliers added and 39 suppliers reviewed.

During the reporting period



Standardizing Green Procurement

Da Ren Tang carries out procurement activities in accordance with the principles of standardization, transparency, and green development. Based on the characteristics of different materials and business operations, the Company has established a procurement organizational system with a clear division of responsibilities and formulated and implemented the "Production Materials Procurement Management Measures of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited" and the "Non-production Materials Procurement Management System of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited". These systems specify requirements for key processes, including procurement planning, price formation, contract signing, and performance management, ensuring compliant and orderly procurement operations.

The Group's Supply Chain Management Center coordinates procurement needs for both the industrial and medicinal material segments. Centralized procurement is implemented based on market conditions, inventory levels, and production plans, and all business units strictly follow these arrangements, effectively balancing procurement costs and supply stability.

Meanwhile, Da Ren Tang actively builds a green supply chain by integrating green procurement principles into institutional design and procurement practices. Environmental protection, resource conservation, health and safety, recycling, and low-carbon development are systematically considered in procurement decisions. Priority is given to environmentally friendly materials that promote energy saving, water conservation, and material efficiency, guiding upstream and downstream partners to jointly promote the development of a green and sustainable industrial chain.

Digital Empowerment

Da Ren Tang continues to advance digital platform development to improve the transparency and efficiency of procurement and supply chain management. Both the industrial and medicinal material segments have fully implemented the "Tianjin Pharmaceutical Digital Procurement (SRM)" platform, enabling full-process online management covering supplier qualification review, access management, procurement sourcing, order execution, and supplier response, and covering key stages across the procurement value chain. During the reporting period, the Company simultaneously promoted the upgrade of its new ERP system and carried out bidirectional integration between the SRM platform, the new ERP system, and the master data system. Through system coordination and data integration, data barriers were eliminated, and the refined and collaborative management of suppliers was further enhanced.

05 Advancing Social Benevolence and Creating Enduring Value

Drug Accessibility Assurance	99
Social Responsibility Enhancement	102
Rural Revitalization Support	106
Industry Development Promotion	107



- Medical Accessibility
- Social Contribution
- Rural Revitalization
- Industry Cooperation and Development

Da Ren Tang integrates social responsibility into its business practices and rooted in the mission of the pharmaceutical industry, closely aligns corporate development with social well-being. Focusing on improving drug accessibility, promoting public welfare and social contributions, supporting rural revitalization, and advancing industry collaboration, the Company continuously optimizes resource allocation and action pathways. Through steady and long-term initiatives, it extends high-quality pharmaceutical services and social value to broader areas, responding to societal expectations with sustained commitment.



Medical Accessibility

Da Ren Tang continuously optimizes product supply and service models in response to medication needs across different regions and populations. By combining the expansion of online channels with overseas market development, the Company promotes broader accessibility, affordability, and sustainable supply of traditional Chinese medicine products, actively responding to public health needs.

Expanding product coverage

Domestic market

In retail channel development, the Company implements a refined regional strategy by managing 336 prefecture-level cities across the country through a tiered system and adopting customized "one-city-one-strategy" solutions to achieve precise resource allocation. The Company has deepened cooperation with national and regional leading chain pharmacies (626 chains), established Da Ren Tang dedicated counters, actively expanded retail pharmacy networks, and deployed O2O platforms. Through a network of nine regional subsidiaries, Da Ren Tang's retail business now covers all provinces and 336 prefecture-level cities nationwide, with diversified product distribution.

In the development of medical channels, the Company systematically reviewed the national coverage of its products and leveraged the channel advantages of Suxiao Jiuxin Wan to promote the coordinated expansion of other products. In regions with relatively weaker coverage, such as the Northwest, the Southwest, and South China, cooperation with local medical associations was strengthened, and academic activities were organized to improve terminal coverage. In the primary healthcare market, the Company expanded the coverage of primary medical institutions through education and training programs supported by grassroots healthcare associations. For key tertiary hospitals that have not yet adopted the products, research collaboration projects were used to facilitate product access. During the reporting period, the Company's medical channels covered all provincial-level administrative regions across China except Taiwan.

In the development of e-commerce channels, the Company established the "E-commerce Channel Medical Accessibility Management Plan of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited" to coordinate product deployment and service support. Leveraging platforms such as JD Health and Alibaba Health, the Company's products have achieved nationwide coverage and continue to expand into lower-tier markets, improving access to medicines in remote and grassroots areas. Currently, the Company's products cover 29 provincial-level administrative regions across China, spanning multiple therapeutic areas including tonics and throat treatments.

Overseas market

In overseas market expansion, the Company has steadily promoted the internationalization of its products. Product exports cover Singapore, Hong Kong, Macao, Japan, the Philippines, Indonesia, Malaysia, Canada, the United States, Russia, North Korea, and New Zealand, among other countries and regions. During the reporting period, the Company continued to advance product registration and filing in key markets such as Singapore, Hong Kong, and Macao. A total of 14 product registration certificates have been obtained in Singapore, and progress has been made in product registration and non-drug filings in Hong Kong and Macao, laying the foundation for compliant product supply in these markets.



A total of **14** product registration certificates have been obtained in Singapore

Reducing healthcare costs

Guided by a people-oriented philosophy, the Company scientifically formulates reasonable pricing while strictly ensuring product quality. Some products have been included in the National Reimbursement Drug List, enabling patients to access high-quality traditional Chinese medicine services and contributing to public health and well-being. In terms of affordability, the Company optimizes product pricing structures by leveraging promotional mechanisms on e-commerce platforms to improve affordability and market competitiveness. As of the end of the reporting period, Da Ren Tang had 279 products included in the national medical insurance catalogue and 103 products included in the National Essential Medicines List.

As of the end of the reporting period




Da Ren Tang had **279** products included in the national medical insurance catalogue



and **103** products included in the National Essential Medicines List

Meeting the needs of specific groups

The Company's products support patient health management throughout the entire lifecycle—from prevention, health maintenance, treatment, and rehabilitation to longevity—providing comprehensive protection for patient health. Its products cover 13 major therapeutic fields, including cardiovascular and cerebrovascular diseases, respiratory diseases, digestive diseases, dermatology, wellness and health preservation, rheumatic and bone pain, urinary diseases, gynecology and pediatrics, ophthalmology, oncology, tonics, chronic diseases, and other areas.



In response to the needs of key population groups, Da Ren Tang Group actively responds to the national "Silver Hair Program" policy and has participated in the *Pilot Program for Age-friendly and Barrier-free Reform of Drug Instructions* issued by the National Medical Products Administration. The Company introduced small honeyed pill dosage forms and provides online pharmacist consultation services for elderly users to enhance convenience and safety in medication guidance. It has also innovated the reading format of drug instructions by developing its own digital platform integrating "digital human video + electronic instructions + voice broadcasting" and other age-friendly functions, enabling different groups to obtain medication information more conveniently and accurately, lowering the threshold for rational medication use, and continuously improving the accessibility and inclusiveness of traditional Chinese medicine services.

In 2025, among the first batch of age-friendly drug instructions approved and filed by the Tianjin Medical Products Administration for market launch, 71 specifications of six key products of Da Ren Tang Group—including Angong Niu Huang Wan and Qinggong Shoutao Wan—were included. This initiative has been widely welcomed and recognized by patients.



Health education

In 2025, Da Ren Tang focused on the prevention and treatment of cardiovascular and cerebrovascular diseases while also addressing seasonal health preservation in traditional Chinese medicine and the health management needs of elderly populations. The Company established a three-in-one health education communication system integrating "disease prevention – emergency knowledge – wellness guidance", and carried out coordinated online and offline health education activities.

Diverse health education activities include

- Planning and implementing a large-scale public welfare initiative centered on the "Da Ren Tang Suxiao Jiuxin Public Welfare Initiative". The initiative includes projects such as emergency knowledge training camps (aiming to train 10,000 certified first-aid responders), community public welfare days, nationwide campaigns to find "good-hearted heroes", and cooperation with delivery platforms to launch cycling emergency rescue volunteers, aiming to enhance public awareness of cardiovascular health and emergency response.
- Organizing seasonal health preservation and health management lectures in grassroots communities, integrating the cultural heritage of traditional Chinese medicine, and distributing "warm care packages" to residents, serving more than one thousand middle-aged and elderly people.
- Launching a series of online public welfare livestreams titled "Anqing Brain Care" through the "Da Ren Tang Care" mini-program to provide practical health knowledge for pharmacy staff and the public.



aiming to train **10,000** certified first-aid responders

Our annual targets and progress are as follows:

FY2025 Target	FY2025 Progress
Improve medical accessibility	<ul style="list-style-type: none"> ● The Company currently has 279 products included in the national medical insurance catalogue and 103 essential medicine products. In 2025, the Company established nine regional subsidiaries covering the entire country, further optimizing regional organizational structures and personnel allocation. ● In the medical channel, the Suxiao Jiuxin Wan Academic Lighthouse Program and the Qingyan Diwan Ten-Thousand-Terminal Coverage Program were implemented; in new retail, more product categories were launched on e-commerce platforms and cooperation with Meituan Pharmacy, JD Instant Delivery and Taobao Flash Purchase strengthened O2O instant retail, further improving product accessibility; overseas, 26 products obtained international registrations in Singapore and other countries and regions, laying the foundation for overseas expansion.
Conduct academic support and health education activities.	<ul style="list-style-type: none"> ● Support multi-level health education and academic promotion activities, including national case-sharing conferences, academic conferences at various levels, and seminars. ● Support the establishment of 5,606 public welfare assistance stations. A total of 81 emergency knowledge training camps were conducted nationwide, training more than 20,000 volunteer responders. ● Three online health education livestreams were organized jointly with chain pharmacies and experts from tertiary hospitals, attracting more than 110,000 viewers.
FY2026 Target	Planned Actions
Improve medical accessibility	<ul style="list-style-type: none"> ● Strengthen the operational effectiveness of the nine regional subsidiaries and integrate medical and retail businesses, while completing personnel coverage across 336 cities. ● Expand product coverage in medical channels; strengthen cooperation with core retail chains; increase product categories on e-commerce platforms and strengthen O2O instant retail to improve product accessibility; continue expanding overseas product registrations.
Conduct academic support and health education activities	<ul style="list-style-type: none"> ● Carry out academic support initiatives, including medical academic conferences at various levels. ● Conduct health education and public science activities to enhance public health awareness.

Social Responsibility Enhancement



During the reporting period, the Company recorded a total of **13,000** hours of volunteer service

Da Ren Tang actively integrates corporate development with public needs and continues to participate in diverse public welfare initiatives focusing on public health and social safety. By supporting public health campaigns, participating in emergency support, promoting first-aid knowledge, and carrying out charitable initiatives, the Company continuously expands the scope of its social responsibility practices. Through concrete actions, it responds to social concerns and promotes the coordinated enhancement of corporate value and social value. During the reporting period, the Company recorded a total of 13,000 hours of volunteer service.

Social Donation Programs:

- Participated in the "Heartbeat Initiative" public welfare program and donated RMB 0.07 million yuan to the Tianjin Red Cross Foundation for the procurement of AED devices.
- Donated medicines to border defense officers, firefighters, and the earthquake-affected areas of Shigatse in Tibet, with a total value of RMB 2.9828 million.
- Donated medicines to the Tianjin Traffic Management Bureau, with a total value of RMB 0.2272 million.
- Donated medicines to the Health Commission of Rongjiang County, with a total value of RMB 0.2637 million.
- Donated medicines to the Red Cross Society of Qingcheng County, with a total value of RMB 0.1046 million.
- Donated medicines to residents affected by disasters in Wang Fuk Court, Tai Po, Hong Kong, with a total value of RMB 0.9099 million.
- Donated 2,000 "Cooling Care Packages" to the Tianjin Youth Development Foundation, valued at RMB 0.2796 million, to support the Hope Project Health Protection – Cooling Relief Program.
- Donated 5,000 boxes of heatstroke prevention medicines to the Energy and Chemical Workers' Union of the All-China Federation of Trade Unions, valued at RMB 0.099 million, to support frontline industrial workers working under high-temperature conditions.

Case Traditional Chinese Medicine Knowledge Popularization and Youth Volunteer Services

Da Ren Tang continues to promote the "Traditional Chinese Medicine Culture on Campus" program and youth volunteer service initiatives, actively disseminating traditional Chinese medicine culture and fulfilling its social education responsibilities. The Company has visited universities, primary and secondary schools, and kindergartens across various regions to popularize basic knowledge of traditional Chinese medicine among teachers, students, and parents through cultural presentations and interactive experiences. At the same time, the Company's Youth League Committee organizes youth volunteer activities under themed initiatives such as "Lei Feng Month", encouraging young employees to develop their abilities and serve society through public welfare practices. A total of 41 volunteer activities have been carried out, covering nearly 30 schools, with both service duration and audience reach continuing to expand.



A total of **41** volunteer activities have been carried out covering nearly **30** schools

Case Guardians of Traditional Chinese Medicine Culture

During the reporting period, Da Ren Tang continued to launch the "Guardians of Traditional Chinese Medicine Culture" initiative. Through the establishment of an industry alliance for TCM cultural guardians, the appointment of guardians through flag-awarding ceremonies, exhibitions of century-old TCM cultural relics, and experiential activities showcasing intangible cultural heritage skills, the initiative promotes exchanges between northern and southern TCM cultures. Over the past two years, the initiative has expanded to 10 provinces, organizing more than 170 activities and benefiting nearly 16,000 citizens, significantly enhancing the reach and influence of traditional Chinese medicine cultural communication.

the initiative
has expanded to
10 provinces

organizing more than
170 activities

benefiting nearly
16,000
citizens



Case Emergency Support Initiative for Traffic Police Working in High Temperatures

In 2025, Da Ren Tang responded to the health protection needs of frontline traffic police officers working under prolonged summer heat. Through the Tianjin Youth Development Foundation, the Company donated heatstroke prevention and emergency medicines such as Huoxiang Zhengqi Liquid and medicated oil to Tianjin traffic police, with donated supplies valued at approximately RMB 0.2272 million. Representatives of the Group visited multiple traffic police duty locations to deliver emergency cooling medical kits and express their care and support to officers working under high-temperature conditions.



donated supplies valued
at approximately RMB
0.2272
million in summer.



Case Health Protection Initiative for City Marathon Events

During the reporting period, Da Ren Tang actively participated in the 2025 Tianjin Marathon and the Tuobo Lake Marathon. To support event safety and emergency preparedness, the Company systematically established protection measures covering both pre-event preparation and on-site support. Emergency medicines such as Suxiao Jiuxin Wan were provided to participants, and emergency stations, AED equipment, and professional support personnel were deployed along the race routes to enhance the response capability for unexpected incidents.



Case Voluntary Blood Donation Initiative

During the reporting period, Da Ren Tang continued to organize the public welfare blood donation initiative titled "Respect Life, Share Love", actively encouraging employees to participate in public health activities. Two rounds of blood donation activities were conducted, with 66 employees successfully donating blood. Participants included frontline production staff, management personnel, and employees from functional departments, including both repeat donors and first-time participants.



66 employees
successfully donating
blood.



Case Government-Enterprise Joint Safety Promotion Activities

During the Safety Production Month, Da Ren Tang was invited to participate in joint safety promotion activities organized by the government and enterprises. Leveraging the Company's brand influence, safety production education was integrated with the display of corporate health products. Through on-site explanations, product demonstrations, and informational materials, the Company helped promote safety and health knowledge among the public.



Rural Revitalization Support

Rural Revitalization

Leveraging the development of Chinese medicinal herb planting bases, Da Ren Tang actively promotes the integrated development of the medicinal herb industry and local economies. Through standardized, large-scale, and organized planting models, the Company supports rural revitalization initiatives.

Taking the Dujiangyan Ligusticum chuanxiong planting base as a demonstration model, the Company promotes unified technical standards and production management across medicinal herb bases. This approach effectively addresses issues associated with the traditional smallholder economic model, such as fragmented production layouts and information asymmetry between production and sales. It also encourages broader social participation in the medicinal herb industry and continuously expands the scale of the industry.

As of the end of the reporting period, the Group has established a total of 2 GAP bases, 6 "Three-No and One-Full" bases, and 37 traceability bases through self-construction and cooperative construction models, covering a total planting area of more than 26,000 mu. These initiatives have directly created employment opportunities for more than 670 residents and generated approximately RMB 80 million in annual income for local communities. By guiding farmers to actively participate in industrial development, the Company stimulates endogenous development momentum among local farmers, promotes sustainable income growth and stable industry development, and provides long-term and sustainable support for local economic development and rural revitalization.

the Group has established a total of

2 GAP bases

6 "Three-No and One-Full" bases

and
37 traceability bases through self-construction and cooperative construction models

covering a total planting area of more than
26,000 mu

These initiatives have directly created employment opportunities for more than
670 residents

and generated approximately RMB
80 million in annual income for local communities.



Based on the requirements for high-quality development in the pharmaceutical industry, Da Ren Tang continues to strengthen cooperation and exchanges with industry associations, industry partners, research institutions, and universities. The Company actively participates in the development of research platforms in key fields, the formulation of standards, and collaborative industry innovation. By promoting deeper integration of industry, academia, and research, and focusing on advantageous product categories and key technological breakthroughs, the Company continuously strengthens the innovation foundation of traditional Chinese medicine, promotes the transformation of research outcomes, and enhances industry capabilities, thereby contributing to the modernization of traditional Chinese medicine and the improvement of the industry system.

Case Establishing a Musculoskeletal Health Research Center to Promote Innovation in Traditional Chinese Medicine

Da Ren Tang collaborated with teams led by Chinese Academy of Engineering Academicians Zhang Boli and Zhu Liguu, together with the Haihe Laboratory of Modern Traditional Chinese Medicine, to establish the "Musculoskeletal Health Research Center". The center conducts systematic research on the application of traditional Chinese medicine in musculoskeletal health, focusing on product clinical value positioning, clinical research, and secondary development of major product varieties, and promoting the transformation of scientific research outcomes into health management and product innovation.



Case Promoting Innovation in Traditional Chinese Medicine Varieties through Industry-Academia-Research Collaboration

Focusing on key areas such as cardiovascular and cerebrovascular diseases, Da Ren Tang jointly organized category development planning seminars with Tianjin University of Traditional Chinese Medicine and the Haihe Laboratory of Modern Traditional Chinese Medicine. These seminars systematically reviewed the development foundations and future directions of core products. Based on an analysis of existing research achievements and market performance of key products, the meetings further clarified the pathways for product optimization, upgrading, and new product development in the coming year, facilitating precise alignment between research resources and industrial needs.



Case Advancing University-Enterprise Collaborative Innovation and International Cooperation

Da Ren Tang continues to deepen university-enterprise cooperation and actively promotes collaborative innovation, integrating industry, academia, and research. The Chairman of the Company led a delegation to the University of Macau for research exchanges and attended the annual meeting of the "University of Macau-Da Ren Tang Traditional Chinese Medicine Innovation Joint Laboratory". In-depth discussions were conducted on topics including the development of the joint laboratory, the transformation of scientific research outcomes, and medium- to long-term research planning. At the same time, leveraging Macau's policy and geographic advantages in the internationalization of traditional Chinese medicine and external cooperation, the Company explores collaborative development models targeting international markets.



During the reporting period, Da Ren Tang also conducted bilateral academic exchanges with the University of Milan in Italy to support the internationalization of traditional Chinese medicine. Through research discussions at the University of Milan and invited lectures by visiting professors, both sides deepened consensus on research collaboration, academic exchanges, and cooperation models in the field of traditional Chinese medicine, laying the foundation for future international cooperation.





Building foundations through standards and driving industry upgrading through leadership, Da Ren Tang Group fully leverages the advantages of its full industry chain layout and actively leads or participates in the formulation and upgrading of national and industry standards. With rigorous methodologies and a scientific approach, the Company integrates its technological expertise with industry development needs to promote the development of more advanced and scientifically grounded pharmaceutical standards. During the reporting period, the quality standards led or participated in by the Company include the following:

 Leading the formulation of **2** national standards

● **Leading the formulation of two national standards:**

Jingwanhong Pharmaceutical led the formulation of the standard for Jingwanhong Hemorrhoid Ointment in the *Pharmacopoeia of the People's Republic of China (2025 Edition)*.

Xinxin Pharmaceutical Plant led the formulation of the drug registration standard for the new product Loxoprofen Sodium Gel Patch.

 Participating in the formulation of **1** national standard

● **Participating in the formulation of 1 national standard:**

No. 6 Chinese Medicine Plant, together with the Tianjin Institute for Drug Control, optimized and revised the content determination method for Suxiao Jiuxin Wan in the *Pharmacopoeia of the People's Republic of China (2025 Edition)*.

 Participating in the formulation of **2** association standards

● **Participating in the formulation of 2 association standards:**

Da Ren Tang Group, as the lead editor, jointly compiled the association standard *Technical Specification for the Production of Internal-use TCM Paste Preparations* (T/ZGCIT 042—2025) with well-known institutions, including Beijing University of Chinese Medicine. The standard has been officially released and implemented within the industry, standardizing the production technology for internal-use TCM paste preparations.

The Chinese Medicinal Pieces Factory participated in the formulation of the China Association of Traditional Chinese Medicine standard *Processing Excipients for Chinese Medicinal Pieces – Part 1: General Principles* (T/CATCM 035.1-2025), which has been officially released and implemented in the industry, standardizing the categories, quantities, and standards of excipients used in the processing of traditional Chinese medicine.

At the same time, the Company has joined multiple industry associations and professional organizations to strengthen industry exchanges and experience sharing.

No.	Association Name	Membership Type
1	China Nonprescription Medicines Association	Senior Vice Chairman Member
2	China Association of Chinese Medicine	Executive Director Member
3	Tianjin Pharmaceutical Industry Association	Vice Chairman Member
4	Tianjin Small and Medium-sized Enterprises Association	Vice Chairman Member
5	Tianjin Price Association	Director Member
6	Beijing Health Economics Association	Member
7	Tianjin Medical Insurance Research Association	Member
8	Tianjin Pharmaceutical Commercial Association	Member
9	Tianjin Health Promotion and Education Association	Member
10	2026 Traditional Chinese Medicine Respiratory Health Development Community	Member Organization



Appendix 1 of the Report Key ESG Performance

Environmental²

Energy Consumption		Unit	2024	2025
Purchased Electricity Consumption	Ten thousand kWh		2,251.22	2,154.51
Natural Gas	Ten thousand m ³		181.13	162.91
Diesel	Tons		93.60	105.51
Gasoline	Tons		4.63	2.28
Purchased Heat	One million kJ		85,776.04	75,609.56
Total Energy Consumption	Tce		8,243.94	7,549.98
Solid Waste		Unit	2024	2025
Hazardous Waste	Tons		584.66	461.79
Hazardous Waste Intensity	Tons/m ²		0.003	0.002
Non-hazardous Solid Waste	Tons		2,462.15	3,385.34
Non-hazardous Waste Intensity	Tons/m ²		0.01	0.02
Total Waste Recycled and Reused	Tons		-	3,254.66
Wastewater		Unit	2024	2025
Wastewater Discharge	Tons		156,150.83	148,644.50
Wastewater Discharge Intensity	Tons/m ²		0.75	0.72
COD Discharge in Wastewater	Tons		24.95	12.68
Suspended Solids Discharge in Wastewater	Tons		7.73	7.89
Total Phosphorus Discharge in Wastewater	Tons		0.04	0.26
Total Nitrogen Discharge in Wastewater	Tons		1.01	1.54
Ammonia Nitrogen Discharge in Wastewater	Tons		-	25.11
Water Consumption		Unit	2024	2025
Total Water Consumption	Tons		248,600	231,200
Water Intensity	Tons/m ²		1.20	1.11
Recycled Water Volume	Tons		-	1,890,000
Water Saved	Tons		-	2,500

2. The environmental data covers Darentang Pharmaceutical Factory, Long Shun Rong Pharmaceutical Factory, Le Ren Tang Pharmaceutical Factory, No. 6 Chinese Medicine Plant, Xinxin Pharmaceutical Plant, Zhongxin Pharmaceutical Plant, Darentang (Tianjin) Traditional Chinese Medicine Decoction Pieces Co., Ltd. (达仁堂中药(天津)饮片公司), Tianjin Da Ren Tang (Bozhou) Chinese Medicine Co., Ltd., Jingwanhong Pharmaceutical and NewScen Coast.

3. Scope 1 greenhouse gas emissions include emissions generated from the consumption of natural gas, gasoline and diesel. The emission factors for natural gas, gasoline and diesel are sourced from the 2019 Refinement to the 2006 IPCC Guidelines for National Greenhouse Gas Inventories published by the Intergovernmental Panel on Climate Change (IPCC). Scope 2 greenhouse gas emissions include emissions generated from purchased electricity and heat. The emission factor for purchased electricity is sourced from the 2023 average grid emission factor for the North China regional power grid released by the Ministry of Ecology and Environment of China, while the CO₂ emission factor for purchased steam is sourced from the Guidelines for Accounting and Reporting Greenhouse Gas Emissions for Enterprises in Other Industrial Sectors(Trail).

Greenhouse gases ³	Unit	2024	2025
Scope 1 Greenhouse Gas Emissions	tCO ₂ e	4,228.38	3,870.12
Scope 2 Greenhouse Gas Emissions	tCO ₂ e	24,689.63	22,021.89
Total Greenhouse Gas Emissions (Scope 1 + Scope 2)	tCO ₂ e	28,918.01	25,892.01
Greenhouse Gas Emission Intensity (Scope 1 + Scope 2)	tCO ₂ e/m ²	0.14	0.12

Air Emissions	Unit	2024	2025
Nitrogen Oxides	Tons	0.77	0.73
Sulfur Oxides	Tons	0.04	0.05
Particulate Matter	Tons	0.31	0.74
Volatile Organic Compounds	Tons	1.35	2.07

Social

Employment and Diversity		Unit	2024	2025
Number of employees	Persons		3,855	3,890
Total number of employees by gender	Female		1,909	1,958
	Male		1,926	1,932
Total number of employees by age	Under 30		424	466
	30 (inclusive) to 50 (exclusive)		2,849	2,849
	50 and above		562	575
Total number of employees by educational background	Master's degree and above		272	349
	Bachelor's degree		1,845	1,952
	Junior college		1,098	1,075
	Below junior college		620	514
Total number of employees by employment type	Full-time		3,835	3,890
	Part-time		0	0
Total number of employees by job level	Senior management ⁴		65	52
	Middle management		171	199
	General and technical staff		3,599	3,639
Total number of employees by region	Tianjin		2,810	2,751
	Other regions of mainland China		1,012	1,124
	Outside mainland China (including Hong Kong, Macao, and Taiwan)		13	15

Employee Turnover		Unit	2024	2025
Total number of employees leaving	Persons		158	167
Employee turnover rate	%		4.12	4.3
Number of new employees hired	Persons		141	331
Internal employee mobility rate	%		-	7.8

4. The statistical scope of senior management personnel refers to the core senior management personnel of the parent Company of the Group and its various subsidiaries and branch Companies.

Occupational Health and Safety		Unit	2024	2025
Number of Work-related Fatalities	Persons		0	0
Work-related Safety Accidents (General Level or Above)	Cases		0	0
Number of Occupational Disease Cases	Person-times		0	0
Occupational Disease Incidence Rate	%		0	0
Employee Training		Unit	2024	2025
Employee training investment	RMB 10,000		-	424.54
Total employee training attendance	Person-times		37,172	38,091
Employee training coverage rate	%		100	100
Total Training Hours	Hours		250,717	256,575
Average training hours per employee	Hours		-	66
Employee Rights		Unit	2024	2025
Labor contract signing rate	%		100	100
Social insurance coverage rate	%		100	100
Employee Assistance		Unit	2024	2025
Total person-times of assistance for employees in need	Person-times		-	over 310
Total employee assistance investment	RMB 10,000		-	75
Supplier Management		Unit	2024	2025
Total Number of Suppliers	Suppliers		541	648
Product Responsibility		Unit	2024	2025
Product Pass Rate	%		100	100
Number of Product Recalls	Cases		0	0
Customer Service		Unit	2024	2025
Number of Quality Complaints	Cases		-	181
Customer Satisfaction (E-commerce)	%		-	96.2
Anti-corruption		Unit	2024	2025
Corruption Litigation Cases	Cases		0	0
Intellectual Property		Unit	2024	2025
Total number of valid patents /trademarks of the Company	Invention patents		241	241
	Utility model patents		78	76
	Design patents		93	90
	Trademarks		1,116	1,668



Appendix 2 of the Report Glossary

Certain entity names used in this report have been abbreviated. The details are as follows:

Abbreviation	Name
COSO	Committee of Sponsoring Organizations of the Treadway Commission
GAP	Good Agricultural Practice
GSP	Good Supply Practice
GVP	Good Pharmacovigilance Practice
GMP	Good Manufacturing Practice
ICH	International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
ICH-Q9	International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use-Quality Risk Management
TGA	Therapeutic Goods Administration
CNAS	China National Accreditation Service for Conformity Assessment



Appendix 3 of the Report Index

Self-Regulatory Guidelines for Listed Companies No. 14 of the Shanghai Stock Exchange – Sustainability Report (Trial)⁵

No.	ESG Topic in the Company's ESG Report	Materiality Analysis	Corresponding Topic in SSE Sustainability Reporting Guidelines
1	Compliance and Risk Control	Double Materiality	-
2	Corporate Governance	Impact Materiality	-
3	Product Quality and Safety	Double Materiality	Product and Service Safety and Quality
4	Waste Disposal	Double Materiality	Waste Treatment
5	Employee Rights and Compensation	Double Materiality	Employees
6	Occupational Health and Safety	Double Materiality	Employees
7	Emission of Pollutants	Double Materiality	Emission of Pollutants
8	Environmental Compliance Management	Double Materiality	Environmental Compliance Management
9	Addressing Climate Change	Double Materiality	Addressing Climate Change
10	Energy Management	Double Materiality	Energy Management
11	Resource Management	Double Materiality	Water Resource Utilization
12	Employee Training and Development	Double Materiality	Employees
13	Responsible Marketing	Financial Materiality	-
14	Customer Rights and Privacy Protection	Financial Materiality	Data Security and Customer Privacy Protection
15	Anti-Bribery and Anti-Corruption	Impact Materiality	Anti-Bribery and Anti-Corruption
16	Research and Innovation	Impact Materiality	Innovation-driven Development Technology Ethics
17	Medical Accessibility	Impact Materiality	Product and Service Safety and Quality
18	Circular Economy	Impact Materiality	Circular Economy
19	Rural Revitalization	Impact Materiality	Rural Revitalization
20	Sustainability Governance	Impact Materiality	Stakeholder Communication Due Diligence
21	Supply Chain Management	-	Supply Chain Security
22	Social Contribution	-	Social Contribution
23	Employee Employment and Diversification	-	Employees
24	Industry Cooperation and Development	-	Innovation-driven Development
25	Biodiversity	-	Ecosystem and Biodiversity Protection
26	Anti-monopoly and Fair Competition	-	Anti-unfair Competition

SGX Listing Rule 711B

No.	Dimension	Relevant Section
a	Material ESG Issues	Identification of Material Issues
aa	Climate-related Disclosure	Addressing Climate Change
b	Policies, Practices, and Performance	Upholding Benevolence and Strengthening Our Century-Old Foundation; Following the Rhythm of Nature and Safeguarding Lucid Waters and Lush Mountains; Inheriting Ancient Craftsmanship and Cultivating Talents of Shared Aspiration; Adhering to Pharmaceutical Integrity and Forging the Quality of Da Ren Tang; Advancing Social Benevolence and Creating Enduring Value; Key ESG Performance Indicators

5. With respect to the topic of "Equal Treatment of SMEs" under the Self-Regulatory Guidelines for Listed Companies No. 14 of the Shanghai Stock Exchange – Sustainability Report (Trial), the Company does not fall under the circumstances specified in Article 46. This topic is currently not considered material and is therefore not discussed in detail in this report.

No.	Dimension	Relevant Section
c	Targets	Compliance and Risk Control Enhancement, Business Ethics Adherence, Environmental Compliance Management, Green Operations Implementation, Addressing Climate Change, Employee Training and Development, Employee Rights and Compensation, Employee Safety Assurance, Quality and Safety Assurance, Customer Rights and Interests Protection, Drug Accessibility Assurance
d	Sustainability Report Framework	About The Report
e	Board Statement	Statement from the Board of Directors



Appendix 4 of the Report Reader Feedback Form

To continuously improve our ESG performance and further enhance our ESG management capabilities and standards, we sincerely welcome your comments and suggestions. Please assist us by completing the feedback form below and returning it to us through one of the following channels.

Address: No. 17 Baidi Road, Nankai District, Tianjin, China

Fax: +86-022-27020892

Email: drt600329@163.com

Your Information

Name	
Relationship with the Company	
Contact Number	
Email	
Feedback	

1. What is your overall evaluation of the Company's ESG report?

Excellent Good Fair

2. Do you think this report reflects the material impacts of the Company's ESG issues?

Yes Partially Not sure

3. How do you evaluate the clarity, accuracy, and completeness of the information, data, and indicators disclosed in this report?

Very high High Moderate Low Very low

4. Which aspect of this report are you most satisfied with?

5. What additional information would you like to learn more about?

6. Do you have any other suggestions for this report?